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Recent perspectives forecast a new paradigm for future “third generation” vaccines based
on commonalities found in diverse pathogens or convergent immune defenses to such
pathogens. For Staphylococcus aureus, recurring infections and a limited success of vac-
cines containing S. aureus antigens imply that native antigens induce immune responses
insufficient for optimal efficacy.These perspectives exemplify the need to apply novel vac-
cine strategies to high-priority pathogens. One such approach can be termed convergent
immunity, where antigens from non-target organisms that contain epitope homologs found
in the target organism are applied in vaccines.This approach aims to evoke atypical immune
defenses via synergistic processes that (1) afford protective efficacy; (2) target an epitope
from one organism that contributes to protective immunity against another; (3) cross-
protect against multiple pathogens occupying a common anatomic or immunological niche;
and/or (4) overcome immune subversion or avoidance strategies of target pathogens.Thus,
convergent immunity has a potential to promote protective efficacy not usually elicited by
native antigens from a target pathogen. Variations of this concept have been mainstays
in the history of viral and bacterial vaccine development. A more far-reaching example is
the pre-clinical evidence that specific fungal antigens can induce cross-kingdom protec-
tion against bacterial pathogens. This trans-kingdom protection has been demonstrated in
pre-clinical studies of the recombinant Candida albicans agglutinin-like sequence 3 protein
(rAls3) where it was shown that a vaccine containing rAls3 provides homologous protec-
tion against C. albicans, heterologous protection against several other Candida species, and
convergent protection against several strains of S. aureus. Convergent immunity reflects
an intriguing new approach to designing and developing vaccine antigens and is considered
here in the context of vaccines to target S. aureus.
Keywords: Staphylococcus aureus, vaccines, NDV-3, Als3, convergent immunity, convergent antigen
INTRODUCTION
Staphylococcus aureus infections are ubiquitous, potentially life-
threatening, and a rising public health issue (1–3). On an indi-
vidual basis, skin and skin structure infections (SSSI) due to S.
aureus are among the most frequent of clinical complaints and
often complicate unrelated medical procedures (4, 5). Based on
2005 data, over 14 million individuals sought clinical care for SSSI
that year in the United States alone (6). More recent data esti-
mate the actual incidence of S. aureus infections to be 600 per
100,000, projecting to exceed 1.5 million SSSI due to S. aureus
each year in the United States (7). Of these, approximately 80,000
yield life-threatening invasive infections annually in the U.S (8–
10). Moreover, nearly 15% of patients (roughly 12,000 per year)
contracting invasive S. aureus succumb to this infection (11). From
a broader perspective, the widespread use of antibiotics to treat
SSSI is costly and raises the selection pressure favoring increas-
ing drug resistance (12). Methicillin-resistant S. aureus (MRSA)
strains are now common agents of community-based outbreaks
(1, 3, 13). Thus, despite a diminishment in MRSA infections in
adults in recent years (9), the incidence of invasive infections due to
MRSA remains unacceptably high. In contrast to adults, no signifi-
cant reduction in healthcare-associated MRSA infections has been
observed in children (14). To the contrary, populations vulnerable
to S. aureus infections extend beyond the immune compromised,
and increasingly include otherwise healthy populations for which
no endogenous risk factors have been identified (15, 16).
Beyond SSSI, invasive infections due to S. aureus are life-
threatening and increasingly impervious to even the most modern
antibiotics. Infections of skin and skin structure, along with muco-
cutaneous colonization burden also impose significantly greater
risk of invasive infections. Compared to non-carriers, elderly men
with high-burden of MRSA nasal colonization develop infections
at a fourfold greater frequency than non-colonized individuals
(17). In addition, greater burden of skin and mucosal colonization
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imparts a greater risk for long-term readmission and mortality
in MRSA-colonized veterans (18). Moreover, a history of MRSA-
positive clinical culture is a significant positive predictor of risk for
community-onset invasive MRSA infection following hospital dis-
charge (19). Further, high density nasal colonization by MRSA also
increases the risk of invasive disease (20). The incidence of inva-
sive community-acquired MRSA infections in children increased
significantly from 2005 to 2010 (14).
From these perspectives, vaccine-mediated protection against
S. aureus disease overall, and MRSA infections in particular, holds
promise to address significant unmet patient needs, leading to sig-
nificant public health benefit. Beyond mitigating SSSI, vaccines
that reduce nasal or mucocutaneous burden of MRSA are also
likely to reduce the risk of life-threatening invasive infections. In
addition, use of effective vaccines has the potential to enhance
antibiotic efficacy or mitigate resistance, by reducing overall use
and allowing more selective application of these drugs. Thus,
efficacious vaccines targeting S. aureus are urgently needed.
INSIGHTS FROM NATURAL HOST DEFENSE AGAINST S.
AUREUS
A primary factor likely resulting in limited success to date in devel-
opment of an efficacious vaccine against S. aureus is an incomplete
understanding of key host-defense mechanisms responsible for
natural protective immunity. Immunologic determinants relevant
to host defense against S. aureus infection may be organized into
recognition, regulation, or effector systems. Optimization of these
systems, individually and synergistically, is necessary for efficacy
in novel vaccines targeting this organism.
MEDIATION OF IMMUNE RECOGNITION
Pattern recognition receptors [PRRs; e.g., toll-like receptors
(TLRs) or nucleotide-binding oligomerization domain like recep-
tors (NLRs)] and their ligation by cognate pathogen-associated
molecular patterns (PAMPs) trigger specific signal transduction
pathways. These circuitries include myeloid differentiation factor-
88 (MyD88), IL-1 receptor-associated kinase (IRAK), inhibitor
of κB kinase (IκBK), and nuclear factor κB (NFκB) activation
cascades. Their activation yields up-regulation of host-defense
peptide and cytokine expression (21–24). Deficient TLR-mediated
responses (25) emphasize the importance of these circuits in rapid
defense against S. aureus infection. Immune dysfunctions that ren-
der patients at increased risk of S. aureus infection (26–28) include
deficient TLR or TLR-mediated response pathways [e.g., MyD88,
IRAK-4, IL-1R (21, 25, 27)], and dysfunctions in IL-1β induction
(29, 30). Insightful reviews of these topics can be found elsewhere
(31–33).
IMMUNE REGULATION
In 2008, Renner et al. (27) identified a dominant polymorphism in
the gene encoding signal transduction/activator of transcription-
3 (STAT3) that was associated with recurring infections due to
S. aureus or other opportunistic pathogens. Because STAT3 is
key to the differentiation of Th17-polarized T cells, this con-
dition is associated with recurring infections often observed in
Job’s Syndrome (also called Hyper-IgE syndrome or Buckley Syn-
drome). In response to IL-6 and TGFβ or IL-23 elaborated by
antigen-presenting cells (APC), Janus-activated kinase-2 (JAK2)
phosphorylates and activates STAT3. In turn, the phosphorylated
STAT3 (STAT3P) activates the transcription factor RAR-related
orphan receptor γτ (RORγτ), and to a lesser extent RORγα. These
events lead to expression of IL-17A and other members of the
Th17 cytokine circuitry, including IL-22. We and other groups
have demonstrated that the IL-17 pathway (IL-17A, IL-22, host-
defense peptides) is of particular relevance to immune defense
against S. aureus infection. Interestingly, αβ and γδ CD4+ T cells
may contribute differently to induce the Th17 pathway in distinct
tissue contexts (34, 35). Excellent reviews of this concept can be
found elsewhere (31, 36) As discussed below, it is important to
note that both IL-17 and IL-22 significantly influence the function
of innate immune effector systems against S. aureus, including
neutrophils and host-defense peptides.
Resident γδ T cells are key to early containment and clearance
of S. aureus at the interface of skin and mucosa (37). However,
γδ T cells do not appear to induce IL-22 in relation to the IL-17
pathway in mouse models (38), and mice deficient in αβ T cells
have dysfunctional abscess formation in S. aureus wound infec-
tion models (39). Moreover, IL-17A/F deficiency predisposes to
spontaneous dermatologic infection, but not hematogenous infec-
tion by S. aureus in some mouse models (40). Thus, vaccines that
induce protective CD4+ αβ and γδT cell-mediated responses may
optimize protective efficacy against S. aureus SSSI.
In addition to the Th17 response, a Th1 response may also
play a role in defense against infection due to S. aureus. Our
laboratory and others have shown that interferon-γ (IFN-γ) is
actively induced in response to S. aureus infection (41). Further,
Cho et al. showed that IL-1β is of special importance to effective
host defense of the skin (42). Paralleling the activation of STAT3
in Th17 responses, Th1 responses are mediated by STAT4 activa-
tion in response to signaling by IFN-γ and IL-12. Phosphorylation
of STAT4, largely via JAK1, induces expression of T-box protein
expressed in T cells (Tbet), which then promotes interferon regula-
tory factor-9 (IRF9) to up-regulate type I (IFN-α and β) and type II
(IFN-γ) interferons. Although the role of type I interferons in host
defense against S. aureus is not well understood, IFN-γ is likely to
play a role in cell-mediated immunity against this and other oppor-
tunistic pathogens. It is notable that infections due to S. aureus are
significantly more common in individuals affected by HIV than in
HIV-negative populations. This relationship supports the impor-
tance of cell-mediated adaptive immunity and T-cell regulation in
effective host defense against this pathogen. Interestingly, in some
models, neutralization of IFN-γ may actually enhance the host
defense against recurrent S. aureus skin infection (43), potentially
by de-repression of Th17 pathways.
It should also be emphasized that natural infection caused by
S. aureus elicits a robust antibody response in immune compe-
tent individuals. In contrast to the Th17 or Th1 paradigms, a Th2
response plays a key role in the induction of antibodies in response
to S. aureus. In this circuit, IL-4, IL-5, and IL-13 are the signa-
ture cytokines for CD4+ T-cell polarization to a Th2 response.
The signaling pathway that mediates this response involves STAT6
activation of the GATA3 transcription factor (44). Importantly,
colonization in the absence of frank infection may be insuffi-
cient to induce high Ab levels. Alternatively, even if baseline Ab
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levels are elevated in healthy individuals as a result of coloniza-
tion, infection due to S. aureus induces a further rapid increase in
Ab levels. Thus, the exposure and response of B cells to staphylo-
coccal antigens is an acute aspect of the adaptive immune response
to this organism. As will be discussed below, whether a protective
or durable anamnestic response occurs in response to S. aureus
infection remains a central question in natural infection, and is a
key goal of novel S. aureus vaccines.
IMMUNE EFFECTORS
In healthy individuals, S. aureus colonizes human skin and mucosa
without causing overt disease, and without inflammatory host
defenses. This fact suggests differences in fundamental aspects
of host defense against S. aureus colonization versus invasion.
Moreover, specific molecular or cellular effectors, and their coordi-
nation, likely differ in distinct tissues (e.g., mucocutaneous versus
hematogenous), or in different stages of infection (acute versus
chronic). Mindful of these caveats, effectors involved in anti-
staphylococcal host defense of relevance to potential mechanisms
of protective vaccines are reviewed below.
Mechanochemical barrier
Initial insights from the Human Microbiome Project (NIH) have
affirmed that S. aureus is a predominant and common member
of the human microbiome (45). The structure and chemical com-
position of intact skin are key features that normally ward off
S. aureus opportunistic infection. From the continuous exfolia-
tion of the epidermis, to its antimicrobial chemistry as reflected
in sebum, salt, and pH conditions shaped by sebaceous, eccrine,
and apocrine glands, the human skin imposes a mechanochemical
barrier to S. aureus invasion (46). Additionally, ceramides, squa-
lene, and wax esters likely contribute to cutaneous defense against
S. aureus (47). Such factors have not been traditionally considered
accessible to vaccines or anti-infective immunotherapies.
Host-defense peptides
Human skin and mucosa are perfused with a variety of host-
defense peptides. Principal structural classes are the defensins,
cathelicidins, and other molecules including S100A7 (psoriacin)
and dermcidin (48). Prototypic α-defensin,β-defensin, and cathe-
licidin class molecules are human neutrophil peptide-1 (hNP-
1), β-defensin-2 (hβD-2), and LL-37, respectively. Microbicidal
chemokines (kinocidins) derived from platelets and other cells also
defend against S. aureus and other infections (24, 49). The regu-
lation, structural biology, and mechanisms of action of these and
related molecules are the topics of other reviews (50–52). New
evidence is emerging that host-defense peptides may be inducible
by vaccination in protection against S. aureus SSSI (see below).
Humoral immunity
B lymphocytes and antibodies may contribute to protec-
tion against mucocutaneous colonization or invasive infection
caused by S. aureus. First, functional antibodies can promote
opsonophagocytosis (FcγRII equivalent receptor-mediated), neu-
tralize extracellular virulence determinants (e.g., secreted exotox-
ins), or potentiate targeted complement fixation (e.g., IgG dimers
or IgM via the classical pathway). For example, the anti-Panton–
Valentine leukocidin antibody (anti-LukAB) emerges in transition
from acute-phase to convalescent sera in children with invasive
S. aureus infection (53). Second, B cells are now increasingly rec-
ognized as integral to antigen presentation (54, 55) and cytokine
conditioning of T-cell responses (56). It should also be recognized
that generation of IgG antibody subclasses 1 or 3 (IgG1 or IgG3)
in humans is dependent upon CD4+ T-cell activation of B-cell
subclass switching. Thus, such antibody responses are subordi-
nate to T-cell regulation, emphasizing the essential roles of T cells
in humoral and cell-mediated immunity to S. aureus.
The potential risks of inducing opsonophagocytic antibodies in
patients having overt or cryptic granulocyte dysfunctions should
also be recognized. S. aureus is a facultative intracellular pathogen
capable of at least temporary survival in the harsh phagolyso-
some of the neutrophil. Thus, even if antibody targeting S. aureus
is capable of promoting opsonophagocytosis in vitro, unless the
granulocyte can rapidly kill the organism, opsonization could
simply facilitate phagocytosis for immune avoidance and cryp-
tic dissemination. This mechanism of immune subversion by S.
aureus has been hypothesized in P47phox null mice by Pancari
et al. (57).
Complement
Complement cascades afford molecular bridges between innate
and adaptive immunity. Lectin and alternative-pathway comple-
ment fixation can both occur in response to PAMPs such as
teichoic acid and peptidoglycan on the S. aureus surface (58). By
comparison, classical complement fixation leverages the humoral
response to guide complement targeting of S. aureus. Here, the
C1qrs complex targets antigen-specific antibody on the organism
surface. Complement fixation also yields opsonins such as C3b
and C5b, which decorate the organism for opsonophagocytosis by
professional leukocytes. Furthermore, anaphylatoxin products of
complement protein cleavage (e.g., C3a and C5a) support leuko-
cyte chemotaxis to sites of S. aureus infection. Activation of the
antimicrobial mechanisms of these cells (reactive oxygen species,
hypohalous reactants, cleavage of antimicrobial peptides, granule
mobilization, etc.) occurs en route to sites of infection (59).
Neutrophils and other host cells
Neutrophils (or polymorphonuclear leukocytes) represent the pre-
dominant cellular effectors of host-defense against S. aureus. This
fact is supported by numerous clinical conditions in which lack of
functional neutrophils, or dysfunctions in neutrophils are associ-
ated with increased risks of S. aureus infection: (a) neutropenia
(60–63); (b) dysfunctions in granulocyte oxidative burst [e.g.,
chronic granulomatous disease; (64, 65)]; (c) dysfunctions in Th17
polarization, which recruits/activates neutrophils [e.g., Job Syn-
drome; (66, 67)); and (d) dysfunctions in leukocyte adhesion
molecule expression or function as required for neutrophil mar-
gination and diapedesis to target sites of infection [e.g., LAD-1 and
-2; (68, 69)]. Less clear are the roles of cells in protection against
S. aureus infection. These include the monocyte/macrophage lin-
eage, natural killer (NK), and perhaps even CD8+ T cells. For
example, up to 50% of S. aureus organisms that are phagocytized
by neutrophils survive intracellularly. Normally, macrophages
in-turn efferocytose S. aureus-containing neutrophils, thereby
enabling effective clearance. However, intra-neutrophil S. aureus
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appear to cause neutrophil up-regulation of CD47, preventing
their effective efferocytosis by macrophages, thus facilitating sur-
vival and potential metastatic seeding of S. aureus (70). Effi-
cacious vaccines will need to overcome such S. aureus survival
mechanisms.
Other effectors
The direct antimicrobial activities of kinocidins (microbicidal
chemokines) are likely to play important roles in defense against
S. aureus infection (49). For example, through IL-12 elaboration,
dendritic cells appear to induce and coordinate CXC, CC, and
other kinocidins (71). Recent evidence has also uncovered previ-
ously unforeseen relationships that offer insights into host-defense
against S. aureus on one hand, and polymicrobial host–pathogen
relationships on another. For example, infection with influenza
suppresses NADPH oxidase-dependent opsonophagocytic clear-
ance of bacteria by macrophages and neutrophils in mouse models
(72). In turn, susceptibility to secondary MRSA infection is signif-
icantly increased. On another front, invariant natural killer/T-cell
(iNKT) receptor-expressing cells can produce IL-17A indepen-
dently of IL-6 co-stimulation. Hence, iNKT cells also may promote
protective inflammatory responses to S. aureus infection. Further,
IL-1 and IL-23 elaboration is necessary for sustained IL-17A/F and
IL-22 generation by iNKT cells in response to S. aureus (73). More-
over, IL-1 and IL-23 generated by PAMP-stimulated dendritic cells
can also induce in vitro IL-1 and IL-23 secretion from NK1.1− cells,
which are iNKT cells principally found in the skin and peripheral
cutaneous lymph nodes. In parallel, CD8+ T cell-mediated clear-
ance of S. aureus-infected host cells has been reported in a murine
model (74). Mice exposed to heat-killed S. aureus generate robust
CD8+ T-cell responses when CD40 ligand is co-stimulated with
specific antibody, yielding protective efficacy in a mastitis model.
Such examples suggest that historically unappreciated molecules
and cells are likely integral to host defense against S. aureus, and
may be integral to creating efficacious vaccines.
THE CHALLENGE OF NORMAL FLORA IN VACCINE
DEVELOPMENT
Co-evolution with mammals has uniquely enabled S. aureus to
occupy a specialized niche as a part of the normal bacterial micro-
biota (75). Thus, the human immune system is faced with a
balancing act: hold the organism at bay, without evoking unneces-
sary inflammation. Yet, why S. aureus transitions from a harmless
commensal to an opportunistic pathogen remains a mystery in
many cases? For example, acquired deficits in host-defense mech-
anisms (e.g., neutropenia) are clearly associated with increased
risk of invasive S. aureus infection. However, more subtle or even
cryptic conditions, alone or in combination, may also render a host
at increased risk of infection. Further, certain virulence factors of
S. aureus may correlate with an increased propensity to cause an
opportunistic infection, as might interactions with other normal
flora. Some of the factors that could mitigate such an opportunistic
infection are discussed below.
INFLUENCE OF OTHER VACCINES ON S. AUREUS COLONIZATION
Vaccines targeted to pathogens other than S. aureus have been
observed to produce significant increases in colonization by
S. aureus in vaccine recipients. Specifically, use of the 7-valent
pneumococcal conjugate vaccine, which reduces both nasopha-
ryngeal colonization as well as disease due to serotypes included
in the vaccine, can increase the frequency of S. aureus colonization
in those receiving the vaccine versus unvaccinated controls (10.1
versus 5.0%, respectively) (76). Additionally, the use of live atten-
uated influenza vaccine has been shown to increase the carriage
density of and duration of colonization by S. aureus, much like
what has been observed with wild-type influenza virus (77). This
phenomenon is most likely due to a reestablishment of the equi-
librium of the microbiome, but could also be due to a deviation
of the immunological profile of some individuals such that they
become better hosts for S. aureus.
IMPACT OF MICROBIOME ON IMMUNE POLARIZATION
The impact of the human microbiome on the immunological pos-
ture of individuals and their response to vaccines is a relatively new
field. Explorations such as those by Eloe-Fadrosh et al. (78) provide
insight that the microbiome can greatly influence polarization of
the immune system. In their particular study, individuals harbor-
ing a more diverse and complex microbiome community exhibited
a multiphasic cell-mediated immune response to an oral typhoid
vaccine. In contrast, Ferreira et al. (79) speculated that the more
diverse microbiome of individuals from developing countries may
account for the suppressed immune response to several vaccines
as is observed relative to more developed countries.
Observations that commensal bacterial and commensal
pathogens leave an immunological “footprint” in the form of
detectable humoral and cell-mediated immune response to some
surface proteins are common [e.g., Ref. (80–82)] and not alto-
gether unexpected. Combined, these observations suggest that
the mere presence of S. aureus in the microbiome should not
be expected to be sufficient to explain or predict the readiness of a
given immune system to respond to a vaccine targeting S. aureus.
IMPACT OF IMMUNIZATION ON MICROBIOME
It is well established that vaccines targeting select serotypes of bac-
terial pathogens (e.g., Streptococcus pneumoniae, Neisseria menin-
gitidis) are very successful at reducing or eliminating serotypes that
are represented in the vaccine. However, it is also evident that such
vaccination can result in serotype replacement with non-vaccine
serotypes of the same or related organisms [e.g., Ref. (83, 84)].
Additionally, potential synergistic relationships between specific
commensal pathogens, such as observed between S. aureus and
Candida albicans (85), C. albicans and Pseudomonas aeruginosa
(86), and P. aeruginosa and S. aureus (87). These relationships sug-
gest that altering the microbiome composition via immunization
may have broader impact by creating a less favorable environment
for synergistic pathogens.
EXPERIENCE IN PRIOR USE OF NATIVE S. AUREUS ANTIGENS
To date, there have been at least 19 S. aureus vaccine clinical studies
conducted in the US (see Table 1) that have evaluated over 20 dif-
ferent antigens (see Table 2). Although much of the data remain
proprietary, all of these antigens had to have been successfully
evaluated in one or more animal challenge studies and shown to
be safe and immunogenic when evaluated in pre-clinical toxicity
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Table 1 | Vaccines containing S. aureus antigens that have been evaluated in human clinical trials as reported on clinicaltrials.gov.
Sponsor Vaccine Antigens Clinicaltrials.gov
identifier
Clinical Study
Phase
Nabi StaphVAXa CP8 conjugate, CP5 conjugate NCT00071214 3
NCT00130260 3
NCT00211900 3
NCT00211913 3
NCT00211926 3
NCT00211965 3
NCT00211991 3
GSK GSK2392 4-component NCT01160172 1
Pfizer SA3Ag CP8 conjugate, CP5 conjugate, clumping factor A NCT01018641 1
SA4Ag Same as SA3Ag plus manganese transporter C NCT01364571 1
SA4Ag and SA3Ag NCT01643941 1, 2
Merck V710a Iron surface determinant B NCT00303069 1
NCT01324440 1
NCT00735839 1
NCT00822757 1
NCT00572910 2
NCT00518687 2, 3
NIAID STEBvax Enterotoxin B NCT00974935 1
Uniformed services Monovalents Alpha toxin NCT01011335 1, 2
University of the
Health Sciences
Panton–Valentine leukocidin toxoid
Bivalent Alpha toxin, Panton–Valentine leukocidin toxoid
aDevelopment terminated.
CP, capsular polysaccharide.
studies to be considered for clinical evaluation. Thus, insufficient
immune response in humans may be one factor that has limited
the number of these vaccine candidates advancing to Phase 2 stud-
ies. To date, no S. aureus vaccines have been demonstrated to have
efficacy for any specific disease indication in humans. For example,
two of the vaccines that were advanced to Phase 2b/3 studies did
not demonstrate efficacy (88, 89) and one of those, using the IsdB
antigen, revealed potentially significant safety issues in cardiotho-
racic surgery patients (89). All of these antigens induce antibodies
in human vaccines, many of which have been shown to have func-
tional activity against S. aureus isolates. Furthermore, several of
these vaccines have been demonstrated to induce T-cell responses,
including IL-17A and IFN-γ. Even so, there is still no clear evi-
dence for or consensus on surrogate markers of protection against
any S. aureus indication. Recently, a tetravalent S. aureus vaccine
was advanced into a Phase 2/3 clinical trial (NCT01643941; see
Table 1). Whether this vaccine will be more efficacious than its
predecessors remains to be determined.
THE PARADOX OF RECURRING S. AUREUS INFECTION
A mystery regarding human infections caused by S. aureus is
the propensity of this organism to cause recurring infections
due to poor efficacy of anamnestic response in a significant
proportion of the overall population. There are several potential
and non-exclusive explanations for this observation.
IMMUNE SUBVERSION
Staphylococcus aureus is known to have a wide array of viru-
lence factors and immune subversion mechanisms. These strate-
gies include dysregulating T-cell responses via superantigens,
disabling host-defense peptides via protease elaboration, avoid-
ance of complement and antibody activities by capsular expres-
sion, and suppression of phagocyte chemotaxis and phagocytosis.
The specific mechanisms of immune subversion by S. aureus
are the topic of other excellent reviews (95–97). Interestingly,
Skurnik et al. recently identified natural antibodies in normal
human sera that inhibit antibody targeting the S. aureus cap-
sule (98). This observation raises the possibility that anti-idiotypic
or other auto-antibodies diminish otherwise protective humoral
immunity versus S. aureus. Thus, even if a perfectly appropri-
ate and otherwise efficacious natural immune response were to
be induced by a vaccine, it may not be fully or even detectably
effective due to direct or indirect immune subversion mediated by
S. aureus.
INEFFECTIVE ANAMNESTIC RESPONSE
An anamnestic response to infection requires the presence and
function of long-term immune memory cells. Relevant to S.
aureus infection, mucosal FCRL4+/CD27− B memory cells, as
well as lymphoid FCRL4−/CD27+ B memory cells are likely
required for sustained or rapidly inducible antibody formation
(99). Beyond B cells, CD45RA−/CCR7+ memory T cells in
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Table 2 | Vaccine antigens targeting S. aureus that have been evaluated in human clinical trials.
Antigen Description Sponsor Clinical study
phase
Reference
CP8 conjugate
CP5 conjugate
PVL
Hla
CP8 conjugated to rEpA
CP5 conjugated to rEpA
Panton-Valentine Leukocidin
toxoid
Alpha hemolysin
GSK No public disclosure. GSK purchased the Nabi
pentavalent S. aureus vaccine (PentaStaph) in 2011
(http://globenewswire.com/news-release/2011/04/27/44
5328/219830/en/Nabi-Biopharmaceuticals-Completes-
Final-PentaStaph-TM-Milestone.html)
SEB Enterotoxin B NIAID (90, 91)
Protein 1
Protein 2
Protein 3
Protein 4
No public disclosure of the
identity of the antigens.
Novartis 1 N/A
Cbp
Clf
Fbp
Eap
Collagen-binding protein
Clumping factor
Fibronectin binding protein
Extracellular adherence protein
Vaccine Research
International
http://www.vri.org.uk/PhaseITrial.pdf
IsdB Iron surface determinant B Mercka (82, 89)
CP5 conjugate CP5 conjugated to CRM197 Pfizer 1, 2 (92)
CP8 conjugate CP8 conjugated to CRM197
Mntc Manganese transporter C
ClfA Clumping factor A
rAT
rLukS-PV
Alpha hemolysin
Panton-Valentine Leukocidin
toxoid
Uniformed Services
University of the
Health Sciences
http://www.empr.com/bivalent-s-aureus-vaccine-
demonstrates-good-immunogenicity-and-neutralizing-
activity/article/314713/
CP8 conjugate CP8 conjugated to rEpA Nabia 1, 2, 3 (93, 94)
CP5 conjugate CP5 conjugated to rEpA
CP336 conjugate CP336 conjugated to rEpA
aDevelopment terminated.
CP, capsular polysaccharide; rEpA, recombinant P. aeruginosa exoprotein A; CRM197, cross-reactive material 197; a non-toxic recombinant variant of diphtheria toxin
(Corynebacterium diphtheriae).
lymph nodes, and CD45RA−/CCR7−effector memory T cells in
mucocutaneous settings are believed to contribute to anamnes-
tic responses (100, 101). In recurring infections due to S. aureus,
it is likely that such anamnestic response mechanisms are either
sub-optimal, or subverted by the pathogen. For example, a recent
analysis by Fowler and Proctor (102) posits that antibody is
not the primary mechanism of host defense against S. aureus
disease. Their review of the literature yielded no causal rela-
tionship connecting IgG deficiency or hypogammaglobulinemia
with increased propensity for S. aureus infection. Thus, vaccine
strategies that solely induce anamnestic humoral responses tar-
geting native antigens face challenges based on natural history
of S. aureus infection in humans. In parallel, phenol-soluble
modulin (PSM) toxins elaborated by S. aureus may cause dys-
functional antigen presentation by dendritic cells to memory
lymphocytes (103). Moreover, S. aureus-induced dysregulation
of monocyte responses, along with a decreased central memory
CD4+ and CD8+ T-cell response, is associated with invasive
infection due to S. aureus in pediatric populations (104). From
these perspectives, efficacious vaccines targeting S. aureus must,
by necessity, enhance anamnestic responses in ways that include
cell-mediated mechanisms.
EXPLOITATION OF REGULATORY LYMPHOCYTES
In neonates, exposure to S. aureus polarizes naive CD4+ T
cells to a FOXP3+/CD25+/CD127Low phenotype, correspond-
ing to a modulated immune response (105). This response
likely establishes tolerance to colonization early in life. While
such tolerance may prevent a potentially harmful inflamma-
tory response to commensal S. aureus, it may also impair effec-
tive immune responses to invasion or re-infection. Similarly, a
regulatory subset of CD8+/CD11chiT cells has been shown to
emerge in the setting of S. aureus infection (106). This regula-
tory subset may inhibit appropriate CD4+ T-cell polarization in
response to the organism. As above, the capability to overcome
exploitation or dysregulation of appropriate immune responses
is likely necessary for efficacy in novel vaccines targeting S.
aureus.
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APPLYING CONVERGENT IMMUNITY TO INNOVATIVE S.
AUREUS VACCINES
The perspectives above offer broad insight into the multi-factorial
and synergistic quality of natural host defense against S. aureus.
It follows that vaccines affording protective efficacy against this
organism will necessarily stimulate optimal immune defenses to
target the organism and spare host tissues. To this end, a review of
recent studies of vaccine development and evaluation in humans
and experimental models is helpful.
THE PRINCIPLE OF CONVERGENT IMMUNITY
Over the span of evolutionary time, humans and microbes have
developed highly specialized systems by which they may exploit
and protect themselves from one another. A basic premise of
protective immunity is that specific antigens in a given pathogen
can induce protective immunity to that pathogen, referred to as
homologous immunity, and in many cases can afford protection
against various strains of the target pathogen, referred to as het-
erologous immunity [e.g., Ref. (107, 108)]. In a similar context,
microbial pathogens have evolved to exploit specific host fea-
tures for virulence (e.g., adherence and invasion of host cells
to initiate the infection process). Thus, diverse pathogens with
similar host targets and niches may use similar or identical patho-
genesis strategies. The existence of such similar host–pathogen
relationships would logically predict overlaps or even convergence
in immunological defenses that may be targeted by convergent
vaccine antigens. These antigens are structural and/or func-
tional homologs from organisms that have convergent structural
and/or functional characteristics to those found in the target
pathogen. These concepts comprise the principle of convergent
immunity.
As detailed in the discussion above, the human immune
system relies upon an array of PRRs that have been opti-
mized to sense and trigger rapid responses to cognate PAMPs
(Figure 1). In turn, immune responses activated by these trig-
gers have evolved to recruit, activate, and regulate immune
effectors most capable of neutralizing that particular microbial
threat. Even so, co-evolution of normal flora as well as oblig-
ate pathogens has allowed microbes the opportunity to evolve
specialized strategies by which to avert host defenses, enabling
colonization or pathogenesis. Thus, convergent immunogens
induce immune processes surmounting those to which microbes
have already become adapted or resistant and, in theory, afford
protective efficacy.
From this perspective, it follows that the generation of
immunogens that stimulate host defenses not typically encoun-
tered by a given microbe may have advantages in develop-
ment of novel vaccines. This concept of convergent immunity
is similar to that termed “un-natural” immunity (109, 110).
To this end, the era of molecular and cellular technologies
has, in effect, accelerated evolution, such that mankind can
now rapidly create strategic immunogens that are not known
FIGURE 1 | Hypothesized integrated human immune circuitries in
host defense against S. aureus infection. In this illustration, three
distinct immunological compartments are shown. Note that
lymphocytes, phagocytes, antibody, and molecular effectors (e.g.,
host-defense peptides, complement, antibody) may be present in each
immunological compartment. However, specific profiles and roles of
immune effectors may not be identical in each compartment. Vaccines
that apply convergent immunity may be designed to optimize those
defenses against S. aureus that best protect the host in context of
specific compartments.
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to be present naturally in any microbe. Moreover, novel adju-
vants are emerging that provide opportunities to further shape
immune responses to convergent antigens. As a result, it may
be possible to use convergent immunity strategies to stimulate
host defenses that would not be induced otherwise, and which
are highly protective against S. aureus and other high-priority
pathogens. The following discussion considers key concepts in
this respect.
INSIGHTS FROM RECENT HUMAN S. AUREUS VACCINE INITIATIVES
Despite highly meritorious efforts, the development of a licensed,
efficacious vaccine or immunotherapy targeting S. aureus has
been elusive to date (see above). Multiple variables likely con-
tribute to this situation, reflecting the complex host–pathogen
relationship between S. aureus and human beings. Immuno-
logical insights from recent carefully designed vaccine clini-
cal trials may aid in considering potentially improved strate-
gies (Table 3). It should also be emphasized that even
though efforts to-date have not yielded a licensed S. aureus
vaccine, they have greatly contributed to our understand-
ing of basic pathogenesis strategies of this pathogen, and
the human immune responses to it. These advances cannot
be overstated in terms of their positive contributions to the
field and insights into design and development of efficacious
vaccines.
A prominent trend among the approaches exemplified above
is an emphasis on robust antibody responses to the target anti-
gen. While it is likely a contributing factor to human protec-
tion against the pathogen (43, 112–115), induction of humoral
immunity alone may be insufficient to prevent S. aureus infec-
tions (116–118). Moreover, the observed efficacy of some vac-
cines in animal models of S. aureus infection may not entirely
recapitulate human responses for several reasons. First, animal
models often use adjuvants that are not applicable for use in
humans, such as Complete Freund’s adjuvant (CFA). Such adju-
vants may enhance immunity in animals that cannot be gen-
erated in humans using other adjuvants. Second, non-human
mammals may defend against S. aureus via mechanisms that are
not identical to human immunity (119–122). However, recent
studies suggest that S. aureus organisms respond to human
and other mammalian hosts (e.g., mice) in a nearly identical
manner, suggesting consistent targets for vaccines and immune
therapies (123, 124). Beyond these considerations, uncertain-
ties in immune defenses, as well as fundamental host-pathogen
relationships regarding normal flora status, may present special
challenges to the development of an efficacious vaccine targeting
S. aureus.
Thus, the experience to date in the development of vac-
cines targeting native S. aureus immunogens either in single
or multi-antigen formats has provided only limited success.
Even so, important new information has been gained from the
many laudable efforts that have been made toward the devel-
opment of S. aureus vaccines and immunotherapies (Tables 1–
3). From these perspectives, innovative strategies such as vac-
cines applying convergent immunity that capitalize on emerg-
ing insights into efficacious host defense against this organism
are needed.
HISTORICAL INSIGHTS INTO CONVERGENT IMMUNITY IN HUMAN
VACCINES
In the context of vaccine development, “natural” immunity can
be defined as inducing an immune response to an antigen that is
naturally present in or on the target pathogen. This is the fun-
damental basis of vaccine development for most of the 200-year
history of modern vaccine use, which typically reflects the prin-
ciples of homologous and/or heterologous immunity (see above).
Moreover, aspects of convergent immunity have been important
factors in past and present vaccine development. Strategic use of
an antigen that is convergent in structure and/or function to that in
a target pathogen intends the outcome of altering and enhancing
the protective efficacy of the vaccine beyond what can be obtained
using the “natural” antigen. This strategy encompasses the use of
epitope homologs that can effectively serve as surrogates of those
in the target antigen, even though the origins of such homologs
may be unrelated to the target pathogen. Specific examples follow,
and some of these concepts have also been reviewed elsewhere
(109, 125).
Cross-protection between related viral pathogens
Early human trials to develop a vaccine against smallpox were in
fact based on the cowpox virus (126). It was similar enough to the
human smallpox virus that the immune response to the cowpox
virus was sufficient to protect from disease due to the smallpox
virus. This is an early example of using convergent immunity to
successfully defend against a target pathogen.
Table 3 | Comparison of recent clinical trials of active vaccines and passive antibodies targeting S. aureus disease.
Developer Vaccine strategy Target antigen(s) Target patient(s) Immunology Outcome
Nabi Bivalent
polysaccharide-protein
conjugate vaccine
Capsular
polysaccharide types
5 and 8
Chronic hemodialysis
patients
Robust antibody
response; durable for
greaterthan year
Phase 3: trended but did not
statistically reduce incidence of
invasive infection (93)
Inhibitex Passive antibody (no
adjuvant)
Clumping factor A
(ClfA)
Established
staphylococcemia;
neonatal staphylococcemia
Rapid, durable systemic
levels of α−ClfA
antibody
Phase 3: trended but did not
statistically reduce risk of
developing invasive infection (111)
Merck Recombinant protein
with or without
aluminum hydroxide
Iron surface
determinant B (IsdB)
siderophore
Cardiothoracic sternotomy
patients
Robust antibody
response
Phase 2: vaccine potentially
associated with serious
post-operative complications (89)
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Toxoid antigens
A critical evolution in the development of vaccines against specific
bacterial pathogens, in particular Corynebacterium diphtheria and
Clostridium tetani, was the recognition that disease due to critical
toxin(s) could be ameliorated by formaldehyde-treatment or “tox-
oiding” of a native toxin protein [see Ref. (127)], This process also
allows the purified toxoid protein to be used as a direct immunogen
rather than having to use antiserum from toxin-tolerized animals.
Though the main goal of toxoids has been to abrogate toxin activ-
ity, a side-result has been to also create convergent immunogens
successful in generating a protective immune response against the
target organism.
Attenuated live virus vaccines
Since the early days of viral vaccine development, attenuation of
the virulence of the target viral pathogen has been successfully
employed to develop vaccines. Polio, measles, mumps, rubella,
and varicella zoster are perhaps the most common examples of
attenuated viruses used in human vaccines. Though the specific
target of the attenuation may not be fully defined, these biolog-
ical alterations, induced by imposing selection pressures on the
virus under non-natural conditions in non-human viral propa-
gation systems. These strategies include propagation in cells lines
in which the virus had little or no pathogenic impact or reduced
replication temperature, and are often directed to components
of viral replication or intercellular translocation machinery, or to
key viral immunogens responsible for protective immunity. Live
viral vaccines are often attenuated by mutations favored during
replication in non-natural hosts (e.g., influenza in embryonated
chicken eggs). These permanent mutations make the attenuated
viral antigen(s) distinct from those spread through human-to-
human transmission. Ultimately, attenuated live virus vaccines
ameliorate disease by interfering with the initiation or progression
of target viral pathogenesis using immunogens and/or inducing
immune responses not normally observed in nature. In addition,
such approaches often aid in understanding pathogenesis of the
target viral pathogen, and enhancement of immunogenicity to
advance novel and more efficacious vaccines. Similar strategies of
attenuation have also been used in some live bacterial vaccines,
such as the BCG, typhoid, and typhus vaccines.
Consensus sequences in multi-clade HIV vaccines
Early in the efforts to develop a vaccine that would prevent
HIV/AIDS, it was recognized that there were many clades of HIV
and sequence variants of immunogens within each clade. One
solution that has been attempted is the generation of “consensus
sequence” protein antigens that would not align exactly with any
one viral clade, but perhaps represent many or all [e.g., Ref. (128,
129)]. Though a clever concept, this approach has not yet resulted
in protection against HIV disease in clinical trials required for
evaluation. It remains to be seen whether such approaches will
outpace more conventional strategies and lead to the efficacy and
successful licensing of HIV/AIDS vaccines. That achievement will
set the stage to evaluate the utility of natural versus convergent
immunity in this vaccine target. In more recent times, this same
concept is being adopted in the development of new influenza
vaccines (130).
Use of recombinant protein antigens
Recombinant proteins can, but may not, mirror the composition
and higher-order structure of their native template counterparts
(see Designing Convergent Immunogens, below). Even though
recombinant protein immunogens are intended to mimic a spe-
cific native protein, there are often modifications associated with
the expression construct and/or manufacturing process to enhance
productivity, optimize folding, reduce aggregation, or influence
other molecular features. Such changes, the result of intentional
or unintentional modifications in the new protein antigen, can
produce antigens that are structurally and/or immunologically
distinct from those found in the native antigen in the target
pathogen. A simple example is found in the Candida albicans
agglutinin-like sequence 3 (Als3) protein, which contains a six-His
affinity tag to facilitate purification, yet is successful in stimulating
a robust immune response in humans, including those who have
been primed by natural exposure to C. albicans (81). However,
as detailed below, because of intentional truncation and expres-
sion in a heterologous organism (rendering a non-native structure
and glycosylation pattern), the Als3 antigen is no longer native to
C. albicans. Thus, beyond modifications of a native antigen, using
such an immunogen to protect against an organism (e.g.,S. aureus)
other than its original source by exploiting convergent antigen(s)
of the target pathogen illustrates one application of convergent
immunity, i.e., cross-kingdom convergent immunity.
Cross-protection of polysaccharide serotypes in pneumococcal
vaccines
The concept of convergent immunogens is not limited to protein
antigens. A parallel approach is well established for bacterial capsu-
lar polysaccharide antigens. For example, there is some evidence
indicating that serotype 6B conjugate vaccine can cross-protect
against serotype 6A (131) and that serotype 9V conjugate vac-
cine can be effective in protecting against serotype 9A infection
(132). However, cross-protection between serotypes within the
same pneumococcal serogroup remains controversial. Likewise,
previous speculation that serotype 19F conjugate vaccine can pro-
vide cross-protection against serotype 19A is still controversial
(133, 134), with epidemiological data suggesting that the inclusion
of a serotype 19A conjugate component in the second-generation
pneumococcal conjugate vaccine is beneficial (135).
Deleterious immunity
Deleterious immunological consequences may also occur due to
unintended alterations of key immunogenic epitopes, as in the
development of a vaccine targeting respiratory syncytial virus
(RSV). In one case,a formalin-inactivated viral vaccine was formu-
lated with an aluminum hydroxide suspension, commonly used
as an adjuvant for bacterial vaccines. This vaccine, evaluated in
infants and children, led to an immune response that actually
exacerbated the viral infection rather than mitigated it; 80% of
trial participants had to be hospitalized and two infants died (136).
The specific cause of this vaccine failure is still debated, but further
work on this important vaccine target was delayed by more than
30 years before new vaccine candidates were pursued in clinical
trials.
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Central dogma of conventional vaccinology is to use native
antigen(s) from the target organism to induce protective immune
responses against that organism. By comparison, convergent
immunity strategically leverages non-native antigen homologs
(including from organisms other than the target pathogen) to
drive antigen-restricted immune responses against a target organ-
ism. The above examples illustrate how convergent immunity
applies non-native antigen homologs to induce vaccine efficacy.
Variations of this theme have been employed throughout the
history of human vaccine development. Many attenuated live
virus, polysaccharide, and recombinant protein vaccines, where
no intentional manipulation of native antigen primary structure
or composition has occurred, can be considered native anti-
gens. Further, the increasing use of chemical modification of
antigens (e.g., toxoids, conjugation, etc.) or protein sequence
alteration (e.g., fusion proteins or truncated protein antigens)
in licensed vaccines shows the successful application of cus-
tomized native antigens in human vaccines. However, conver-
gent immunity takes this concept one step further: use of a
native or customized native antigen relative to one pathogen,
and apply it to antigen-restricted protection targeting a different
pathogen containing structurally and/or functionally homolo-
gous antigen(s). Thus, native immunity and convergent immunity
are distinct but complementary forces in the design of effica-
cious vaccines. With advances in technology and understand-
ing of protective immune responses, convergent immunity will
almost certainly be leveraged in some form for future vaccine
development, including for development of vaccines targeting
S. aureus.
INSIGHTS FROM USE OF CONVERGENT ANTIGENS IN S. AUREUS
VACCINE STUDIES
In 2008, it was shown that a recombinant protein based on the
N-terminal region of a surface antigen, agglutinin-like sequence
3 protein from C. albicans (rAls3), which had previously been
shown to be an adhesin (137) and an invasin (138), could pro-
tect mice from intravenous challenge with S. aureus (41). This
predicted outcome was based on the discovery that Als3 had a
high degree of structural homology with two surface proteins
on S. aureus, clumping factor A (Clfa) and collagen-binding
protein (Cna) (139). Moreover, the N-terminus of Als3 and
other Als family members have close structural homology to
adhesins and invasins from a number of microbial pathogens,
including Yersinia spp. and other Gram-negative organisms, and
hemagglutinin from influenza virus strains. Studies using rAls3
formulated with aluminum hydroxide (referred to as NDV-3;
see below) and have now established a strong foundation for
pursuing this antigen as an example of applying convergent
immunity to contribute to the development of a successful S.
aureus vaccine.
Murine bacteremia models
Prior studies from our group have demonstrated that immuniza-
tion with the C. albicans rAls3 antigen induces protective efficacy
against MRSA bacteremia in Balb/C mice (41). Further, in the
specific conditions of this model, immunization with rAls3 evokes
protective efficacy against hematogenously disseminated S. aureus
infection in B cell but not T-cell knockout mice. Supporting a
key role for T cells, non-immunized animals were protected by
adoptive transfer of CD4+ T cells from NDV-3 immunized mice
but not by transfer of B220+ B cells or serum from NDV-3
immunized mice. Further, NDV-3 protection against MRSA bac-
teremia was abrogated in IL-17A null mice (140). Collectively,
this body of evidence is consistent with the emerging immuno-
biology of natural S. aureus antigens, in which Th17 pathway
constituents are involved in defense against S. aureus and C.
albicans in mice.
Murine skin/skin structure infection models
Recently, we evaluated the efficacy and immunological mech-
anisms of NDV-3 in mouse SSSI due to MRSA (141). Com-
pared to adjuvant alone, NDV-3 immunization reduced abscess
progression, severity, and MRSA density in skin following chal-
lenge by a variety of strains. Moreover, vaccination by NDV-
3 mitigated hematogenous dissemination to kidneys. Corre-
sponding to this, protective efficacy NDV-3 induced increases
in CD3+ T-cell and neutrophil infiltration, and IL-17A, IL-
22, and host-defense peptide expression in local settings of
SSSI abscesses. These novel findings demonstrate that NDV-
3 efficacy against MRSA in SSSI involves a robust and com-
plementary response integrating innate and adaptive immune
mechanisms.
Bovine mastitis models
Important insights regarding convergent antigen targeting
S. aureus have also derived from recent efforts to control
bovine mastitis. For example, Festa et al. used the domesticated
tobacco plant (Nicotiana tabacum) to express the S. aureus vir-
ulence factor extracellular fibrinogen binding protein (Efb) as
a vaccine immunogen (142). Expression of this bacterial anti-
gen in the context of plant mechanisms of protein synthesis
yields an immunogen that is homologous to the natural anti-
gen. Mice orally immunized with this product have antigen-
specific immune responses, which are likely discernable from
those induced by the native bacterial antigen. The immune
responses to native antigens, such as S. aureus whole cell and
lysate preparations, have also been modified by novel means
such as formulation with the ISCOM matrix adjuvant (143).
This latter adjuvant has been reported to induce higher levels
of specific antibody, as compared to aluminum hydroxide adju-
vant (144). This suggests that an adjuvant can induce/enhance
a non-natural response to a natural antigen. More detailed
studies are needed to characterize the similarities and differ-
ences in immune response to this and other convergent anti-
gens, as compared to those observed using the corresponding
native antigens.
Human vaccination
Evidence for human immune responses to NDV-3 that parallel
those in the above mouse models come from human clinical trials
evaluating the safety, tolerability, and immunogenicity of NDV-3
versus saline placebo (81). NDV-3 formulations containing either
30 or 300µg rAls3 were safe, well-tolerated, and achieved 100%
seroconversion. Peak anti-rAls3 IgGtotal and IgA1 antibody levels
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were detected within 14 days of receiving a single dose of vac-
cine. Moreover, a single dose of NDV-3 resulted in IL-17A and
IFN-γ production from Als3 peptide-stimulated peripheral blood
mononuclear cells (PBMCs) in the majority of vaccinated subjects
within 7–28 days of vaccination. Seven days following a second
dose of vaccine at 6 months post-initial vaccination, a modest
increase was seen in anti-rAls3 IgGtotal and IgA1, essentially reca-
pitulating the first dose antibody response. Importantly, after the
second dose, rAls3-specific IFN-γ-producing PBMCs were found
in 100% of subjects and Als3-specific IL-17A-producing PBMCs
were seen in 50–80% of subjects. Such responses are consistent
with the expectation that humans are naturally exposed only to
the native Als3 antigen as a consequence of ubiquitous exposure
to C. albicans. The robust and durable response to NDV-3 immu-
nization indicates rapid T- and B-cell recognition and response to
the NDV-3 immunogen, and an enduring anamnestic response in
human subjects. Of special note, the immunological determinants
corresponding to protective efficacy elicited by the convergent
antigen in NDV-3 in murine models of invasive staphylococ-
cal infection and SSSI (high anti-rAls3 antibody titers and Th17
responses) are also observed in the human immune response to
NDV-3. Thus, the present findings support the potential for NDV-
3 to prevent or mitigate severity of bacteremia and/or SSSI due to
MRSA or MSSA strains in humans. Taken together, this body of
evidence supports the continued clinical evaluation of NDV-3 as
a vaccine candidate to protect against disease caused by S. aureus
and Candida.
It should also be noted that much remains to be learned
with respect to the critical difference between non-protective and
protective immune responses relative to S. aureus. For example,
among the interesting evidence emerging from the field is the
finding that human antibody generated in response to the rAls3
antigen appears to enhance human neutrophil opsonophagocy-
tosis of target pathogens (145). In contrast, initial findings from
B-cell knock out mouse models of bacteremic S. aureus infection
were interpreted to suggest that B cells, and therefore antibody,
may have lesser roles in host defense against systemic S. aureus
infection in mice (41). The limits of these prior studies should be
recognized and not preclude the potential importance of human
antibody in optimal host defense against SSSI or bacteremia
caused by S. aureus in humans. For example, the importance
of subclass switching, acute versus anamnestic responses, as well
as anatomically targeted antibody (e.g., mucosal IgA versus cir-
culating IgG) remain to be understood with respect to immu-
nity to S. aureus, particularly as regards this convergent vaccine
antigen.
STRATEGIES FOR CONVERGENT VACCINE ANTIGENS TARGETING
S. AUREUS
The considerations detailed above provide an integrated frame-
work for exploring novel convergent vaccine antigens targeting
S. aureus. In effect, there may be other vaccine antigens that have
one or more convergent features related to this target pathogen.
These features may be due, if for no other reasons, to natural
strain-to-strain variations of indigenous pathogens, and the collat-
eral impacts of antigen production processes. However, potentially
more transformative or paradigm-shifting approaches may be
applied to develop convergent vaccine antigens that are specifically
designed to induce protective immunity for S. aureus indications.
The remainder of this article focuses on strategies for design-
ing and producing such antigens to induce convergent immunity
for protection against disease due to S. aureus. The attractive-
ness of exploring convergent immunity in this respect is enhanced
by a lack of success to date with conventional S. aureus-derived
antigens. Collectively, these perspectives suggest that novel strate-
gies will be required to address the challenge and increasing
impact of multi-drug-resistant S. aureus infections with respect
to public health. Although a multi-valent vaccine approach using
native antigens may eventually prove successful, applying con-
vergent immunity strategies is anticipated to accelerate or afford
unique advantages in developing efficacious S. aureus vaccines or
immunotherapies. This view is supported by the historical facts
mentioned above and perspectives considered below.
Parallels in host-pathogen evolution
Divergent microorganisms, even across kingdoms, may develop
identical or highly similar mechanisms to exploit shared targets or
strategies in human hosts. This relationship is illustrated through
the convergent structural, functional, and immunological deter-
minants that transcend biological kingdoms in the fungus Candida
albicans and the bacterium Staphylococcus aureus:
• Candida and Staphylococcus occupy similar anatomical niches
in humans (epidermal/mucosal barriers)
• Both organisms have evolved similar pathogenesis strategies in
humans (mucocutaneous colonization/opportunism/immune
evasion/hematogenous dissemination)
• These organisms appear to share evolutionary parallels in struc-
tural biology [e.g., Als/microbial surface components recogniz-
ing adhesive matrix molecules (MSCRAMMs) are members of
the immunoglobulin superfamily]
• Immunoglobulin superfamily proteins are functional homologs
(e.g., Als3/ClfA and other homologous adhesins and invasins)
• C. albicans and S. aureus interactions appear to synergize in
pathogenesis [e.g., Ref. (85, 146)]
• Immune defenses to both pathogens are alike, relying primar-
ily upon host-defense peptides, induction of Th1 and Th17
pathways, and phagocyte-mediated responses that are likely
potentiated by humoral and complement functions.
It follows that the human host almost certainly employs similar
immune pathways and mechanisms to control these pathogens.
Such relationships afford opportunities to develop innovative
immunogenic agents and strategies including broad-spectrum
vaccines and convergent immunogens that protect against dis-
eases due to opportunistic pathogens such as S. aureus that are
also normal flora.
Cross-kingdom convergent immunogens: Candida and
Staphylococcus
We first identified the structural and functional homology among
Als proteins of Candida albicans, and microbial surface compo-
nents of Staphylococcus and other pathogens using computational
bioinformatics and molecular modeling (139). Using 1° sequence
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homology threading and 3-D structural analysis, we found conser-
vation of key sequence motifs and overall conformational homol-
ogy among Als family proteins. Interestingly,hypervariable regions
in sequences of these family members corresponded to diversity
among extracellular loop regions. Next, we made the discovery
that the N-terminal domains of Als1 and Als3 share unforeseen
structural convergence with corresponding regions in S. aureus
MSCRAMMS considered virulence factors, including clumping
factor A (ClfA) (Figures 2 and 3; Table 4) (139). Similar to Als3
from Candida, such proteins mediate adhesion of S. aureus to
host tissues or cells during pathogenesis. Notably, because Als3
and the S. aureus proteins have relatively low overall sequence
identity (≤23%), their convergent structures would likely have
been missed by sequence alignments alone. Based on this exciting
discovery, we predicted that the rAls3 antigen derived from C. albi-
cans could also induce protective immunity against S. aureus (41).
We have since demonstrated the rAls3 vaccine to have efficacy in
mouse models of hematogenous C. albicans infection (140, 147),
vulvovaginal candidiasis (148), disseminated S. aureus infection
(140), and in SSSI due to MRSA (141). Of importance, as predicted
we found that vaccination with rAls3 induced robust humoral
and cell-mediated immunity in these mouse models, paralleling
responses observed in humans.
Homology among B-cell epitopes. B-cell receptors identify
three-dimensional epitopes, and the rAls3 antigen induces a
strong antibody response in mice, primates, and humans. More-
over, antibodies from humans vaccinated with rAls3 promote
opsonophagocytic activity in vitro against S. aureus (145). There-
fore, the Als3 and homologous S. aureus antigens contain com-
mon immunogenic 3-D epitopes that are recognized by B cells.
We have evaluated the structural features of such epitopes using
FIGURE 2 |The cross-kingdom immunogen rAls3 based on
structure/function homology is shown. Illustrated here are structurally
homologous regions in Als3 (C. albicans adhesin/invasin; model) and ClfA
proteins (S. aureus adhesin; deterministic structure analysis). The structural
model of the Als3 N-terminus was generated as previously described using
sequence threading and molecular dynamics [left; (130, 131)]. The cognate
region in a homolog from S. aureus (clumping factor A; ClfA; right) is
shown for comparison. Both proteins are members of the immunoglobulin
superfamily and known virulence determinants. Note the overall highly
similar three-dimensional β-barrel domains (gold arrows), interposed by
hinge regions.
complementary approaches. First, immune sera from mice and
humans immunized with rAls3 antigen cross react with structural
and functional homologs in C. albicans and S. aureus (Ibrahim and
Yeaman, communication). Second, 3-D computational thread-
ing demonstrated robust conformational homology between Als3
from C. albicans and its functional homologs, for example, clump-
ing factor A (ClfA) and collagen-binding protein A (Cna) of S.
aureus (Table 4), as well as related homologs from other human
pathogens (139). Third, our combinatorial extension analyses
revealed specific conformational epitopes that are consistent with
observed cross-reactivity of rAls3 immune sera to C. albicans and
FIGURE 3 | Structural basis for B-cell epitopes shared in Als3 and ClfA
is shown. Combinatorial extension analysis was used to compare the
model of Als3 with that of the known structure of ClfA. (A) Front view of
the 3-D structural superimposition of homologous structural domains of
Als3 (Candida albicans; gray) and ClfA (Staphylococcus aureus; blue);
(B) rear view of the same region in protein homologs. The discovery,
prediction, and validation of T-cell epitopes in such homologs offers further
promise in design of innovative convergent vaccine antigens that induce
efficacious cell-mediated immunity. Such striking convergence of linear
(T cell) and 3-D (B-cell) epitopes in proteins with analogous functional and
immunoprotective properties is consistent with the observation that
C. albicans and S. aureus occupy very similar anatomic niches. It follows
that humans have likely evolved common pathways of host defense against
both pathogens, which may be targeted in novel vaccines that leverage
convergent immunity.
Table 4 | Quantitative sequence and three-dimensional structure
homology analysis of C. albicans Als3 and selected homologs from
S. aureus (139).
Protein 1 Protein 2 SeqID (%) SeqSIM (%) RMSD Z score
Als3 (model) 1N67 (ClfA) 9 19 4.82a 5.19b
Als3 (model) 1D2P (Cna) 5 23 5.58 3.29
1N67 (ClfA) 1D2P (Cna) 9 20 5.44 3.50
aSignificance threshold <5.0.
bSignificance threshold <3.5.
ClfA, clumping factor A; Cna, collagen-binding protein.
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S. aureus (Figure 3). Taken together, these findings support the
concept that these pathogens share common 3-D epitopes capable
of inducing cross-reactive antibodies to both organisms.
Homology among T-cell epitopes. Our observations also pointed
to common T-cell epitopes in C. albicans and S. aureus antigens,
including: (1) protective efficacy of rAls3 in animal models of C.
albicans and S. aureus infection; (2) T-cell response profiles indi-
cating that rAls3 induced robust T-cell responses in both mice and
humans; (3) sera predominantly include IgG subclasses that rely
on T cells for B-cell activation and antibody production; and (4)
overall low sequence identity between Als family proteins of Can-
dida and MSCRAMM proteins of S. aureus suggested that regions
where sequence homology did exist would hold insights into T-
cell epitope sequences. Because vaccination of mice with rAsl3
induced protection by mechanisms including T-cell responses,
we applied bioinformatic mining and computational modeling
to predict T-cell epitopes in rAls3. In this process, we predicted an
immunodominant epitope to have the sequence WNFPVSSDSF-
SYT (patent pending). As predicted, this epitope is very similar
to the immunodominant human T-cell epitope of Als3 as exper-
imentally validated by Bar et al. (149). Further, this epitope was
reported to have 10-fold greater MHC-II peptide-binding groove
affinity (264 nM) as compared with any other T-cell epitope, sup-
porting robust predictive accuracy of our immunogen discovery
and design approach.
LEVERAGING CONVERGENT IMMUNITY FOR INNOVATIVE VACCINES
As illustrated above, by discovering non-obvious parallels in
host–pathogen relationships, and exploiting structurally and func-
tionally convergent antigens, we have generated broad-spectrum
vaccines, which induce protective immunity against multiple
pathogens. Our work leverages three tenets: (1) host defenses pro-
tective against pathogens having antigenic or strategic parallels
in pathogenesis may be elicited by convergent vaccine antigens;
(2) bioinformatics integrated with computational systems mod-
eling can reveal and optimize cryptic epitope and immunological
homologies for use in designing convergent immunogens with effi-
cacy against diverse pathogens; and (3) immune defenses may be
optimized to afford protective efficacy in specific anatomic, phys-
iological, immunological, and/or microbiological contexts. These
concepts are consistent with innovative approaches, including
convergent immunity, as illustrated below.
Designing convergent immunogens
Engineered changes are common in recombinant protein anti-
gens. Small changes in the composition, sequence, and structure
between a manufactured vaccine antigen and the native form
of that antigen (e.g., amino acid substitution and/or trunca-
tions of proteins, modification of glycosylation, attenuation of
pathogenic capacity, or replication), have the potential to alter
protective immune responses. If such modifications are too mod-
erate, these strategies are likely to be silent or undecipherable to
the functional immune response. For purposes of this discussion,
we are more concerned with larger changes that are expected to
impose distinct differences from the native antigen. Fundamental
to the design of antigens is the consideration of primary sequence,
post-translational or production process-induced modifications,
higher-order structure, and molecular size and/or aggregation
state.
Linear sequence epitopes. T lymphocytes detect linear peptide
sequence epitopes presented by APC in the context of MHC class
I (e.g., HLA A, B, or C; CD8+ T cells) or MHC class II (e.g., HLA
DP, DQ, DR; CD4+T cells). Thus, vaccines that induce efficacious
T-cell responses rely upon the appropriate presentation of primary
sequence epitopes and ensuing polarization to govern appropri-
ate and protective immune response paradigms (e.g., Th1, Th2,
Th17). As detailed above, vaccines that appear to induce efficacious
responses in experimental models, and those which are immuno-
genic in humans, induce robust biomarkers of T-cell response.
For example, IFN-γ and IL-17A are involved in efficacious vac-
cine responses in mouse models of MRSA bacteremia (41, 140)
and SSSI (141) due to S. aureus, and these same immune response
profiles are observed in humans immunized with this vaccine can-
didate (81). A key to design of efficacious vaccines targeting S.
aureus is the understanding of biomarkers that offer the great-
est insight into protective efficacy. For example, because IFN-γ
and IL-17A counter-modulate one another, vaccines that promote
maximal T- cell induction of such cytokines may not confer maxi-
mal protection. Thus, the identification of optimal T cell-mediated
immune signatures, rather than maximal responses, may provide
new opportunities to develop vaccines targeting S. aureus. More-
over, it remains to be determined whether such biomarkers may be
best sought from bloodstream or tissue-specific biological speci-
mens (e.g., mucosa, lymph node, other). In addition to design of
cognate T-cell epitopes from pathogens themselves, engineering
flanking or other common sequence motifs known to stimulate
T cells and perhaps polarize to a given paradigm (e.g., Th17
versus Th1) is emerging in the design of vaccines that induce
cell-mediated immunity (150).
Higher-order structures. The importance of T-cell responses
in designing efficacious vaccines has received increased attention
with respect to linear immune epitopes. However, large, conforma-
tional antigens designed to induce convergent immune responses
also have emerging promise in the generation of novel efficacious
vaccines. In this respect, a non-exhaustive list of examples might
include the following.
3-D structural homologs. As mentioned above, antibody induc-
tion has been a mainstay of immunization strategies classically.
However, exemplified in the HIV experience and more recently
with S. aureus, antibody alone may not prove to be the opti-
mally protective immune response. However, there is important
crosstalk that occurs between antibody and other immune effec-
tor systems (e.g., phagocytes, complement, etc.). Thus, vaccines
that evoke convergent humoral immunity could be designed
to optimize the most efficacious functional type of antibod-
ies. For example, human IgG1 and IgG3 subclasses typically
interact with Fcγ receptors on professional phagocytes most
efficiently. Therefore, enhancing protective phagocytic defenses
against S. aureus could involve design of convergent immuno-
gens having 3-D structures that evoke high target-affinity Fab
domains, and also promote subclass switching as above to optimize
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Fc-mediated opsonic functions. By comparison, protective immu-
nity requiring complement fixation may best promote induction
of antigen-restricted IgM and IgG2 antibody subclasses, for exam-
ple. Likewise, vaccines intended to protect against colonization or
infection of mucosal surfaces may be optimized to induce secretory
IgA subclasses. Through each of these examples, convergent 3-D
or conformational immunogens provide opportunities to induce
antibody profiles distinct from those induced by B-cell epitopes
inherent to the native antigens themselves. Also important in this
regard is a need for cytokine conditioning and T-cell signaling
for B-cell activation and antibody generation in response to an
antigen. Obviously, recent discoveries point to the importance of
B cells as APC for T-cell activation. Such considerations further
suggest critical immunogenic relationships between T- and B-cell
epitopes needed in an optimally efficacious vaccine.
Fusion constructs. Fusion protein constructs have also been
explored as a means of creating efficient “designer” antigens. This
approach has the advantage that multiple epitopes can be com-
bined into a smaller number of recombinant proteins, assuming
that the essential features of the epitopes can be conserved in
the resulting protein product (Figure 4). A particularly extreme
example of a fusion protein antigen appears to be the Group A
Streptococcus (GAS) vaccine originally developed by ID Biomed-
ical, which consisted of multiple recombinant proteins, each of
which was a fusion of immunogenic regions from a given surface
protein from a total of 26 serotypes of GAS (151).
Fusion constructs may contain structural elements already
demonstrated to be determinants of protective efficacy. In addi-
tion to the known virulence antigens (or immunogenic domains
thereof) that contain fundamental B- and T-cell motifs, fusion
proteins can be further designed to encompass antigens to enhance
mechanisms of efficacy against the target organism(s) (Figure 4).
Immunogenic modules can be interposed by linker domains that
enable high-fidelity presentation of the 3-D structure of each anti-
gen to be maintained (152). Such strategies can also facilitate
appropriate processing of the fusion protein (e.g., proteolysis and
presentation of linear epitopes) by APC for T-cell receptors. Such
modular components will likely impose conformational influences
on one another, and can be rearranged to optimize protective
effects based on in vivo efficacy and immune response. Further-
more, such constructs can be engineered to contain sequences
that enhance antigen-presenting and intrinsic adjuvant effects that
promote ideal polarization of the immune system to the target
pathogen.
Antigen context. Traditionally, many vaccines have been viewed
as protein-based immunogens in solution, functioning individually
to prompt specific responses targeting the cognate antigen(s).
Beyond this view, interactions of antigens, or antigens organized in
macromolecular systems or nanoparticles, afford additional strate-
gies for beneficial impacts of convergent immunity (153, 154). For
example, a protein in solution may have very different conforma-
tional epitopes as compared to the identical protein in context of a
lipid bilayer. As many vaccine antigens derive from membrane-
associated virulence factors, solution-based immunogens may
miss important opportunities to induce protective immunity.
Likewise, distinct antigens may interact with one another in a
vaccine suspension, creating second or greater order epitopes for
immune exposure. From these examples, it is reasonable to antic-
ipate that novel vaccines targeting S. aureus may contain one or
more antigens in conditional states. Development of liposomal or
nanoparticle vaccines allow some immunogens to be presented in
context of biological membrane systems (Figure 5). Such strategies
offer advantages in presenting epitopes so as to engender optimally
protective, rather than maximally quantitative, B-cell responses.
Targeted antigen presentation. It is increasingly apparent that the
human immune system detects immunogenic determinants in
specific contexts that bias specific immune responses. For example,
in mammalian lung mucosa, resident dendritic cells (e.g., class I;
MHCIIhi/CD11b+/CD11c+) appear to detect, process, and traffic
antigens in a manner optimized for MHC class II presentation and
ensuing activation of proximate stromal CD4+ T cells (155, 156).
These functions are not identical in class II monocytic dendritic
cells (e.g., IL-12 secreting), or class V dermal dendritic cells. As a
result, immune responses from such distinct contexts of antigen
processing, presentation, and trafficking can be very different. It
follows that convergent immunity best suited to protect against S.
aureus infections of specific tissue sites or anatomic contexts may
necessarily need to be designed to engage APC most relevant to a
given site. Further, specific vaccines designed to target antigen pre-
sentation to specific T and/or B-cell subsets is a logical extension of
this strategy of convergent immunity (157). These examples illus-
trate the larger concepts that convergent vaccine antigens might
be designed to comprise multi-component sets of core epitopes
engineered to stimulate specific subsets of APC to evoke optimal
host defenses for specific anatomic niche(s).
Post-translational or production process-induced modifications.
Beyond the design of non-natural antigenic sequences or con-
structs themselves, the use of non-native hosts for their expression
affords further dimensions in the generation of antigens for stim-
ulation of convergent immunity. For example, purposeful sub-
stitutions, additions (e.g., six-His tags) and/or truncations are
FIGURE 4 | Conceptual design of modular and combinatorial convergent
vaccine immunogens. Illustrated here is an example of a convergent vaccine
immunogen that integrates multiple antigen motifs (Ag motif ) containing
flanking sequences (Flank ) optimized as T-cell epitopes, interposed by
strategic linker domains (Link ) in a fusion construct. By virtue of its expression
in a strategic heterologous system, glycosylation motifs (Glyco motif ) or lack
thereof would be favored to stimulate or target immune pattern recognition
receptors (PRRs) to evoke optimal responses for protective efficacy.
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FIGURE 5 | Progressive modes for generation of convergent
immunogens are shown. In this example, multiple concepts detailed in
the text are shown in a sequential manner that yields increasingly strategic
convergent immunogens. Approaches such as these are being employed in
design of vaccines to elicit optimally protective immune responses that
include tissue-targeted and cross-kingdom mechanisms of action. These
and related aspects of convergent immunity may be necessary for
efficacious vaccines targeting opportunistic pathogens such as S. aureus.
commonly employed to improve the productivity of expression
cell lines or to minimize or eliminate aggregation of recombi-
nant proteins. Such specifications may be integrated into various
approaches for strategic heterologous expression of a given anti-
gen for optimal induction of protective immunity. These strategies
might also incorporate the choice of a heterologous host organ-
ism, as well as conditions under which an organism is induced to
express an antigen. A non-exhaustive illustration of the spectrum
of potential considerations in this regard might include strategic
uses of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris
non-human mammalian cell lines (e.g., Chinese hamster ovary
cells), or human cell lines. Each has its advantages and drawbacks,
including a greater theoretical potential to generate “humanized”
antigens that, in concept, may have heightened risk of inducing
autoimmune disease.
Combination vaccine products
Identification and development of convergent immunogens such
as rAls3 for an S. aureus vaccine may also complement the use of
native antigens and provide surrogate antigens to induce extended
immunological response. Moreover, this approach represents a
new category of antigen that may be considered in the context
of a combination vaccine product. The choice of antigens to use
in such a combination product is driven by considering multi-
ple factors, including the role of the antigen in the biology of
the organism (e.g., function; accessibility), the uniqueness of the
immunogen with respect to human proteins or other microbial
targets, the type of immune response induced by the antigen,
or a combination of the above. To date, most multi-component
vaccines used in clinical evaluations (see Table 2) have been dri-
ven more so by consideration of the roles of the antigens in the
biology of the organism. In some cases, adjuvants are used to
influence the type of immune response being brought to bear (see
below). However, more recently, consideration is being directed
to a mixed approach that also considers the relationship among
antigens, and types of immune responses they induce with respect
to S. aureus (118, 158, 159).
Adjuvants
The role of adjuvants in vaccines can be considered either as a way
to direct the immune response to the vaccine antigens (e.g., use of
aluminum hydroxide suspension to bias toward a Th2 response)
or as a way to enhance immune responses to the immune stimuli
inherent to a given antigen (e.g., inclusion of aluminum hydrox-
ide does not appear to influence the T-cell response to rAls3).
As such, the inclusion of an adjuvant in a formulation with a
convergent antigen provides yet another opportunity to influence
the immune responses to a vaccine. The real value of the adju-
vant can only be determined by comparative studies in the target
human population to: (1) establish an increase in efficacy with
use of the adjuvant (versus without the adjuvant); or (2) by first
establishing surrogate markers of protection and then observing
the increase in those markers in the presence versus the absence
of the adjuvant. While animal models may be useful in these
respects, final evaluation in humans remains the only convincing
way to establish the value of adding a given adjuvant to a vaccine
formulation.
STRATEGIC IMMUNIZATION REGIMENS
Convergent immunity may also benefit from thoughtful timing
and modes of vaccine administration. With S. aureus being a
commensal pathogen, it stands to reason that most if not all
humans have been primed for S. aureus natural antigens by expo-
sure to the bacterium. In this case, strategic vaccination regimens
that may bias acute or more durable responses might be favored,
depending on whether long-term or short-term immunization
is the objective of vaccination. Long-term efficacy is necessary
in protection against chronic threat of infection, whereas short-
term protection may be sufficient when risk of infection can be
anticipated (e.g., transplantation, chemotherapy, surgery, etc.).
Short-term immunization may only require a single dose of vac-
cine, which in the presence of pre-existing immune response to
the immunogen homolog, can be used to extend the scope of
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natural anamnestic response that enhance convergent immunity.
As has been shown with the rAls3 antigen, the magnitude of this
boost in both B- and T-cell responses may be moderated by the
dose level of antigen administered (81). For vaccines containing
a combination of antigens, the option for a single dose to induce
a natural anamnestic response relies on each antigen having been
primed by natural exposure to the pathogen. Longer-term immu-
nity may require additional doses of vaccine,particularly if a strong
T-cell response is needed. In this situation, doses may be given as
a series of vaccinations over a short period of time to prompt a
robust initial immune response, or given over longer time intervals
(e.g., annually) to maintain an elevated state of immune readi-
ness. However, it should be kept in mind that a maximal immune
response may not be an optimal immune response, as the ultimate
goal is not to induce immune response but to prevent or treat
disease.
Beyond timing, it is increasingly evident that mode of vaccine
administration can have significant impact on immune response.
For example, as above, an identical immunogen that is admin-
istered via intra-muscular, subcutaneous, or even intra-dermal
routes often induce distinctive immune response profiles. These
considerations illustrate the larger concepts that convergent vac-
cine antigens might be designed to comprise multi-component
sets of core antigens that have been engineered to stimulate spe-
cific subsets of dendritic or other APC in such a manner as to
evoke collectively optimal host defenses for specific anatomic
niche(s).
COORDINATE INDUCTION
Protective host defense versus S. aureus requires a highly coor-
dinated and multi-focused immune response. An overarching
strategy in convergent immunity is to develop vaccines or
immunotherapeutics that bring complementary host defenses
together to achieve protection against infection that could not
be achieved by any single immune mechanism alone. This strat-
egy addresses the reality that an infection caused by S. aureus
contains organisms in different growth phases, that occupy dif-
ferent anatomic niches, and that may be refractory to one or
more immune effectors alone. A conceptual example would be
a multi-component vaccine, in which distinct immunogens are
optimized to induce a Th17 response for neutrophil enhance-
ment, Th2 response for induction of IgG1/IgG3 opsonophagocytic
antibodies, and Th22 response to promote the induction of host-
defense peptides most appropriate to act on the target pathogen
in relevant tissues. Such strategies for coordinate induction may
afford advantages in optimizing efficacy via inclusion of both nat-
ural and convergent immunity. It is possible if not likely that
combinations of such strategies will be leveraged in design and
evaluation of multi-valent vaccines targeting S. aureus. It may also
be more realistic than not that distinct vaccines or immunother-
apeutic modalities may be needed to protect against S. aureus
infections of specific anatomic niches or compartments. Such
vaccines would be optimized to marshal the optimally protective
host defenses for a given niche. For example, vaccines designed
to protect mucocutaneous tissues may induce distinct adaptive
and effector mechanisms than those most efficacious in defending
against S. aureus bacteremia. These concepts integrate the realties
that the repertoire of immune targets and virulence strategies of
this organism in distinct compartments are very different, as are
immune responses best to defend against them.
PROSPECTUS
The application and optimization of convergent immunity derives
from historical success in vaccine discovery and development. In
this sense, vaccines that induce protective immunity in response
to antigens, which are non-identical to those found in nature
has many potential advantages in development of improved vac-
cines targeting S. aureus or other pathogens. Yet, much remains
to be learned regarding the secrets by which the human immune
system largely outwits S. aureus on a day-to-day basis. By unlock-
ing these mechanisms, vaccines comprising convergent as well
as natural antigens have the potential to address the public
health concerns imposed by S. aureus and likely other pathogens
as well.
As proposed herein, optimally efficacious vaccines and
immunotherapeutics protective against S. aureus disease will likely
rely upon:
A. A more comprehensive understanding of the critical immuno-
protective mechanisms targeting this organism, including
those that may not be known or fully appreciated at present. A
key to this concept is differentiating non-protective versus pro-
tective immune responses. It follows that specific biomarkers
that prioritize protective immune responses over those, which
are not protective are much needed. Included in these concepts
are molecular and cellular effectors of immunity not tradi-
tionally considered to be active in defense against S. aureus
(e.g., cell-mediated immunity; interactions between innate
host-defense peptides and professional phagocytes, etc.). These
effector mechanisms may be additive or synergistic interac-
tions of immune responses, and/or not currently detected or
prioritized in the evaluation of vaccines.
B. Leveraging of convergent immunity in targeting normal flora
organisms for which there may be pre-existing baseline
immune responses.
C. Innovative design and deployment of convergent antigens as
surrogates of natural antigens that trigger protective immune
responses, which optimize efficacy or promote immunity that
would not otherwise be induced by recapitulation of native
antigens.
D. Immunization regimens and strategies that induce dynamic
and coordinated immune responses that are optimized to
anatomic, physiological, or microbiological contexts best
suited to address S. aureus pathogenesis or immune subversion
strategies.
E. Use of strategic adjuvants to promote antigen-restricted
immune responses that afford protection against the ultimate
target pathogen(s), even if the antigen(s) themselves may not
be native to these pathogens.
F. Combinations of the above that employ strategic use of heterol-
ogous expression, modular antigen design, and emerging tech-
nologies to evoke optimally protective rather than maximally
detectable immune responses, and advances in biomarker
signatures to discern the difference; and
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G. Avoidance of untoward effects in dysregulated or dysfunctional
immune responses to vaccine antigens, including autoimmune
disease.
ACKNOWLEDGMENTS
The authors recognize the many excellent contributions made to
the field of vaccinology in general, and vaccines and immunother-
apeutics targeting Staphylococcus aureus more specifically. We
appreciate the efforts of Dr. Dennis Dixon, Dr. Rory Dun-
can, and other members of the National Institutes of Health,
and U.S. Department of Defense for prior support of programs
aimed to develop innovative anti-infectives targeting high-priority
pathogens. The present manuscript was supported in-part by
grants from the National Institutes of Health [AI111661 (Michael
R. Yeaman), AI19990 (John E. Edwards Jr.), AI063382 (John
E. Edwards Jr.)], and U.S. Department of Defense [W81XWH-
12-2-0101 (Michael R. Yeaman), W81XWH-11-1-0686 (John P.
Hennessey Jr.)].
REFERENCES
1. David MZ, Daum RS. Community-associated methicillin-resistant Staphylo-
coccus aureus: epidemiology and clinical consequences of an emerging epi-
demic. Clin Microbiol Rev (2010) 23(3):616–87. doi:10.1128/CMR.00081-09
2. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis
and erysipelas. J Infect (2012) 64(2):148–55. doi:10.1016/j.jinf.2011.11.004
3. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated
methicillin-resistant Staphylococcus aureus. Lancet (2010) 375(9725):1557–68.
doi:10.1016/S0140-6736(09)61999-1
4. Geria AN, Schwartz RA. Impetigo update: new challenges in the era of methi-
cillin resistance. Cutis (2010) 85(2):65–70.
5. Karamatsu ML, Thorp AW, Brown L. Changes in community-associated
methicillin-resistant Staphylococcus aureus skin and soft tissue infections pre-
senting to the pediatric emergency department: comparing 2003 to 2008. Pedi-
atr Emerg Care (2012) 28(2):131–5. doi:10.1097/PEC.0b013e318243fa36
6. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in
ambulatory visits and antibiotic prescribing for skin and soft-tissue
infections. Arch Intern Med (2008) 168(14):1585–91. doi:10.1001/archinte.168.
14.1585
7. Chambers HF. Community-associated MRSA – resistance and virulence con-
verge. N Engl J Med (2005) 352(14):1485–7. doi:10.1056/NEJMe058023
8. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, et al.
National burden of invasive methicillin-resistant Staphylococcus aureus infec-
tions, United States, 2011. JAMA Intern Med (2013) 173(21):1970–8. doi:10.
1001/jamainternmed.2013.10423
9. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, et al.
Concurrent epidemics of skin and soft tissue infection and bloodstream infec-
tion due to community-associated methicillin-resistant Staphylococcus aureus.
Clin Infect Dis (2012) 55(6):781–8. doi:10.1093/cid/cis527
10. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Inva-
sive methicillin-resistant Staphylococcus aureus infections in the United States.
JAMA (2007) 298(15):1763–71. doi:10.1001/jama.298.15.1763
11. Song X, Cogen J, Singh N. Incidence of methicillin-resistant Staphylococ-
cus aureus infection in a children’s hospital in the Washington metropolitan
area of the United States, 2003-2010. Emerg Microbes Infect (2013) 2(10):e69.
doi:10.1038/emi.2013.69
12. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the
antibiotic era. Nat Rev Microbiol (2009) 7:629–41. doi:10.1038/nrmicro2200
13. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother
(2010) 65(Suppl 3):iii35–44. doi:10.1093/jac/dkq302
14. Iwamoto M, Mu Y, Lynfield R, Bulens SN, Nadle J, Aragon D, et al. Trends
in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics
(2013) 132(4):e817–24. doi:10.1542/peds.2013-1112
15. Catry B, Latour K, Jans B, Vandendriessche S, Preal R, Mertens K, et al. Risk
factors for methicillin resistant Staphylococcus aureus: a multi-laboratory study.
PLoS One (2014) 9(2):e89579. doi:10.1371/journal.pone.0089579
16. Jiménez JN, Ocampo AM, Vanegas JM, Rodriguez EA, Mediavilla JR, Chen
L, et al. A comparison of methicillin-resistant and methicillin-susceptible
Staphylococcus aureus reveals no clinical and epidemiological but molecular
differences. Int J Med Microbiol (2013) 303(2):76–83. doi:10.1016/j.ijmm.2012.
12.003
17. Stenehjem E, Rimland D. MRSA nasal colonization burden and risk of
MRSA infection. Am J Infect Control (2013) 41(5):405–10. doi:10.1016/j.ajic.
2012.07.017
18. Quezada SM, Steinberger EK, Cross RK. Association of age at diagnosis
and Crohn’s disease phenotype. Age Ageing (2013) 42(1):102–6. doi:10.1093/
ageing/afs107
19. Duffy J, Dumyati G, Bulens S, Namburi S, Gellert A, Fridkin SK, et al.
Community-onset invasive methicillin-resistant Staphylococcus aureus infec-
tions following hospital discharge. Am J Infect Control (2013) 41(9):782–6.
doi:10.1016/j.ajic.2012.10.020
20. Datta R, Shah A, Huang SS, Cui E, Nguyen V, Welbourne SJ, et al. High nasal
burden of methicillin-resistant Staphylococcus aureus increases risk of invasive
disease. J Clin Microbiol (2014) 52(1):312–4. doi:10.1128/JCM.01606-13
21. Suresh R, Mosser DM. Pattern recognition receptors in innate immunity,
host defense, and immunopathology. Adv Physiol Educ (2013) 37(4):284–91.
doi:10.1152/advan.00058.2013
22. ZhongY, Kinio A, Saleh M. Functions of NOD-like receptors in human diseases.
Front Immunol (2013) 4:333. doi:10.3389/fimmu.2013.00333
23. Bauer S, Muller T, Hamm S. Pattern recognition by toll-like receptors. Adv Exp
Med Biol (2009) 653:15–34. doi:10.1007/978-1-4419-0901-5_2
24. Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol
(2014) 12(6):426–37. doi:10.1038/nrmicro3269
25. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health
and disease. Nat Rev Immunol (2009) 9(10):679–91. doi:10.1038/nri2622
26. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms
and clinical consequences. Nat Rev Immunol (2004) 4(3):211–22. doi:10.1038/
nri1310
27. Renner ED, Rylaarsdam S,Anover-Sombke S, Rack AL, Reichenbach J, Carey JC,
et al. Novel signal transducer and activator of transcription 3 (STAT3) muta-
tions, reduced T(H)17 cell numbers, and variably defective STAT3 phospho-
rylation in hyper-IgE syndrome. J Allergy Clin Immunol (2008) 122(1):181–7.
doi:10.1016/j.jaci.2008.04.037
28. Horváth R, Roz˘ková D, Laštovicˇka J, Polocˇcková A, Sedlácˇek P, Sedivá A, et al.
Expansion of T helper type 17 lymphocytes in patients with chronic granulo-
matous disease. Clin Exp Immunol (2011) 166(1):26–33. doi:10.1111/j.1365-
2249.2011.04449.x
29. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS,
et al. IL-1 receptor blockade restores autophagy and reduces inflammation in
chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S
A (2014) 111(9):3526–31. doi:10.1073/pnas.1322831111
30. Miller LS, Pietras EM, Uricchio LH, Hirano K, Rao S, Lin H, et al.
Inflammasome-mediated production of IL-1beta is required for neutrophil
recruitment against Staphylococcus aureus in vivo. J Immunol (2007)
179(10):6933–42. doi:10.4049/jimmunol.179.10.6933
31. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infec-
tions. Nat Rev Immunol (2011) 11(8):505–18. doi:10.1038/nri3010
32. Greenberg JA, David MZ, Hall JB, Kress JP. Immune dysfunction prior to
Staphylococcus aureus bacteremia is a determinant of long-term mortality. PLoS
One (2014) 9(2):e88197. doi:10.1371/journal.pone.0088197
33. Metzger DW, Sun K. Immune dysfunction and bacterial coinfections following
influenza. J Immunol (2013) 191(5):2047–52. doi:10.4049/jimmunol.1301152
34. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, et al. IL-17
is essential for host defense against cutaneous Staphylococcus aureus infection
in mice. J Clin Invest (2010) 120(5):1762–73. doi:10.1172/JCI40891
35. Murphy AG, O’Keeffe KM, Lalor SJ, Maher BM, Mills KH, McLoughlin RM.
Staphylococcus aureus infection of mice expands a population of memory gam-
madelta T cells that are protective against subsequent infection. J Immunol
(2014) 192(8):3697–708. doi:10.4049/jimmunol.1303420
36. Krishna S, Miller LS. Host-pathogen interactions between the skin and Staphy-
lococcus aureus. Curr Opin Microbiol (2012) 15(1):28–35. doi:10.1016/j.mib.
2011.11.003
37. Bergstresser PR, Tigelaar RE, Dees JH, Streilein JW. Thy-1 antigen-bearing den-
dritic cells populate murine epidermis. J Invest Dermatol (1983) 81(3):286–8.
doi:10.1111/1523-1747.ep12518332
www.frontiersin.org September 2014 | Volume 5 | Article 463 | 17
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yeaman et al. Convergent immunity for S. aureus vaccines
38. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, et al.
CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococ-
cus aureus wound infections. Proc Natl Acad Sci U S A (2006) 103(27):10408–13.
doi:10.1073/pnas.0508961103
39. Mölne L, Corthay A, Holmdahl R, Tarkowski A. Role of gamma/delta T cell
receptor-expressing lymphocytes in cutaneous infection caused by Staphylo-
coccus aureus. Clin Exp Immunol (2003) 132(2):209–15. doi:10.1046/j.1365-
2249.2003.02151.x
40. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differ-
ential roles of interleukin-17A and -17F in host defense against mucoepithe-
lial bacterial infection and allergic responses. Immunity (2009) 30(1):108–19.
doi:10.1016/j.immuni.2008.11.009
41. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, et al. The
antifungal vaccine derived from the recombinant N terminus of Als3p pro-
tects mice against the bacterium Staphylococcus aureus. Infect Immun (2008)
76(10):4574–80. doi:10.1128/IAI.00700-08
42. Cho JS, Zussman J, Donegan NP, Ramos RI, Garcia NC, Uslan DZ, et al. Non-
invasive in vivo imaging to evaluate immune responses and antimicrobial ther-
apy against Staphylococcus aureus and USA300 MRSA skin infections. J Invest
Dermatol (2011) 131(4):907–15. doi:10.1038/jid.2010.417
43. Montgomery CP, Daniels M, Zhao F, Alegre ML, Chong AS, Daum RS.
Protective immunity against recurrent Staphylococcus aureus skin infection
requires antibody and interleukin-17A. Infect Immun (2014) 82(5):2125–34.
doi:10.1128/IAI.01491-14
44. Zeng WP. “All things considered”: transcriptional regulation of T helper type
2 cell differentiation from precursor to effector activation. Immunology (2013)
140(1):31–8. doi:10.1111/imm.12121
45. Conlan S, Kong HH, Segre JA. Species-level analysis of DNA sequence data
from the NIH Human Microbiome Project. PLoS One (2012) 7(10):e47075.
doi:10.1371/journal.pone.0047075
46. Fischer CL, Drake DR, Dawson DV, Blanchette DR, Brogden KA, Wertz
PW. Antibacterial activity of sphingoid bases and fatty acids against Gram-
positive and Gram-negative bacteria. Antimicrob Agents Chemother (2012)
56(3):1157–61. doi:10.1128/AAC.05151-11
47. Wille JJ, Kydonieus A. Palmitoleic acid isomer (C16:1delta6) in human skin
sebum is effective against gram-positive bacteria. Skin Pharmacol Appl Skin
Physiol (2003) 16(3):176–87. doi:10.1159/000069757
48. Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-
infective peptides. Annu Rev Pharmacol Toxicol (2012) 52:337–60. doi:10.1146/
annurev-pharmtox-010611-134535
49. Yeaman MR, Yount NY. Unifying themes in host defence effector polypeptides.
Nat Rev Microbiol (2007) 5(9):727–40. doi:10.1038/nrmicro1744
50. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resis-
tance. Pharmacol Rev (2003) 55(1):27–55. doi:10.1124/pr.55.1.2
51. Korting HC, Schöllmann C, Stauss-Grabo M, Schäfer-Korting M. Antimicro-
bial peptides and skin: a paradigm of translational medicine. Skin Pharmacol
Physiol (2012) 25(6):323–34. doi:10.1159/000341990
52. Dawson MJ, Scott RW. New horizons for host defense peptides and lantibiotics.
Curr Opin Pharmacol (2012) 12(5):545–50. doi:10.1016/j.coph.2012.06.006
53. Thomsen IP, Dumont AL, James DB, Yoong P, Saville BR, Soper N, et al. Chil-
dren with invasive Staphylococcus aureus disease exhibit a potently neutralizing
antibody response to the cytotoxin LukAB. Infect Immun (2014) 82(3):1234–42.
doi:10.1128/IAI.01558-13
54. Barnett LG, Simkins HM, Barnett BE, Korn LL, Johnson AL, Wherry EJ,
et al. B cell antigen presentation in the initiation of follicular helper T
cell and germinal center differentiation. J Immunol (2014) 192(8):3607–17.
doi:10.4049/jimmunol.1301284
55. Harvey BP, Raycroft MT, Quan TE, Rudenga BJ, Roman RM, Craft J, et al.
Transfer of antigen from human B cells to dendritic cells. Mol Immunol (2014)
58(1):56–65. doi:10.1016/j.molimm.2013.10.013
56. Rodriguez-Pinto D, Saravia NG, McMahon-Pratt D. CD4 T cell activation by B
cells in human Leishmania (Viannia) infection. BMC Infect Dis (2014) 14:108.
doi:10.1186/1471-2334-14-108
57. Pancari G, Fan H, Smith S, Joshi A, Haimbach R, Clark D, et al. Characterization
of the mechanism of protection mediated by CS-D7, a monoclonal antibody to
Staphylococcus aureus iron regulated surface determinant B (IsdB). Front Cell
Infect Microbiol (2012) 2:36. doi:10.3389/fcimb.2012.00036
58. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human
pathogens. Nat Rev Microbiol (2008) 6(2):132–42. doi:10.1038/nrmicro1824
59. Gasque P. Complement: a unique innate immune sensor for danger signals.
Mol Immunol (2004) 41(11):1089–98. doi:10.1016/j.molimm.2004.06.011
60. Quilty S, Kwok G, Hajkowicz K, Currie B. High incidence of methicillin-
resistant Staphylococcus aureus sepsis and death in patients with febrile
neutropenia at Royal Darwin Hospital. Intern Med J (2009) 39(8):557–9.
doi:10.1111/j.1445-5994.2009.02003.x
61. Swati M, Gita N, Sujata B, Farah J, Preeti M. Microbial etiology of febrile neu-
tropenia. Indian J Hematol Blood Transfus (2010) 26(2):49–55. doi:10.1007/
s12288-010-0029-z
62. Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, Grogan L, et al. Emer-
gence of MRSA in positive blood cultures from patients with febrile neu-
tropenia – a cause for concern. Support Care Cancer (2008) 16(9):1085–8.
doi:10.1007/s00520-007-0398-5
63. Shaw BE, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in
a stem cell transplant unit: analysis before, during and after an MRSA outbreak.
Bone Marrow Transplant (2007) 39(10):623–9. doi:10.1038/sj.bmt.1705654
64. Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease.
Clin Exp Immunol (2014) 175(2):139–49. doi:10.1111/cei.12202
65. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G.
Chronic granulomatous disease: a review of the infectious and inflammatory
complications. Clin Mol Allergy (2011) 9(1):10. doi:10.1186/1476-7961-9-10
66. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3
mutations in the hyper-IgE syndrome. N Engl J Med (2007) 357(16):1608–19.
doi:10.1056/NEJMoa073687
67. White CJ, Gallin JI. Phagocyte defects. Clin Immunol Immunopathol (1986)
40(1):50–61. doi:10.1016/0090-1229(86)90068-1
68. Badolato R. Defects of leukocyte migration in primary immunodeficiencies.
Eur J Immunol (2013) 43(6):1436–40. doi:10.1002/eji.201243155
69. Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruit-
ment and its deficiencies. Mol Immunol (2013) 55(1):49–58. doi:10.1016/j.
molimm.2012.11.006
70. Greenlee-Wacker MC, Rigby KM, Kobayashi SD, Porter AR, DeLeo FR, Nau-
seef WM. Phagocytosis of Staphylococcus aureus by human neutrophils pre-
vents macrophage efferocytosis and induces programmed necrosis. J Immunol
(2014) 192(10):4709–17. doi:10.4049/jimmunol.1302692
71. Schindler D, Gutierrez MG, Beineke A, Rauter Y, Rohde M, Foster S, et al. Den-
dritic cells are central coordinators of the host immune response to Staphy-
lococcus aureus bloodstream infection. Am J Pathol (2012) 181(4):1327–37.
doi:10.1016/j.ajpath.2012.06.039
72. Sun K, Metzger DW. Influenza infection suppresses NADPH oxidase-
dependent phagocytic bacterial clearance and enhances susceptibility to sec-
ondary methicillin-resistant Staphylococcus aureus infection. J Immunol (2014)
192(7):3301–7. doi:10.4049/jimmunol.1303049
73. Doisne JM, Tan TC, Colucci F. Guardian of the genome turns on genes
that alert natural killer cells. Cell Cycle (2011) 10(22):3822–3. doi:10.4161/
cc.10.22.18196
74. Wallemacq H, Bedoret D, Pujol J, Desmet C, Drion PV, Farnir F, et al. CD40 trig-
gering induces strong cytotoxic T lymphocyte responses to heat-killed Staphy-
lococcus aureus immunization in mice: a new vaccine strategy for staphylococcal
mastitis. Vaccine (2012) 30(12):2116–24. doi:10.1016/j.vaccine.2012.01.039
75. van Belkum A, Melles DC, Nouwen J, van Leeuwen WB, van Wamel W,Vos MC,
et al. Co-evolutionary aspects of human colonisation and infection by Staphy-
lococcus aureus. Infect Genet Evol (2009) 9(1):32–47. doi:10.1016/j.meegid.
2008.09.012
76. van Gils EJ, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP,
et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococ-
cus aureus colonisation in a randomised controlled trial. PLoS One (2011)
6(6):e20229. doi:10.1371/journal.pone.0020229
77. Mina MJ, McCullers JA, Klugman KP. Live attenuated influenza vaccine
enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus
in mice. MBio (2014) 5(1):e1040–1013. doi:10.1128/mBio.01040-13
78. Eloe-Fadrosh EA, McArthur MA, Seekatz AM, Drabek EF, Rasko DA, Sztein
MB, et al. Impact of oral typhoid vaccination on the human gut microbiota
and correlations with S. typhi-specific immunological responses. PLoS One
(2013) 8(4):e62026. doi:10.1371/journal.pone.0062026
Frontiers in Immunology | Microbial Immunology September 2014 | Volume 5 | Article 463 | 18
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yeaman et al. Convergent immunity for S. aureus vaccines
79. Ferreira RB, Antunes LC, Finlay BB. Should the human microbiome be
considered when developing vaccines? PLoS Pathog (2010) 6(11):e1001190.
doi:10.1371/journal.ppat.1001190
80. Baquir B, Lin L, Ibrahim AS, Fu Y, Avanesian V, Tu A, et al. Immunological reac-
tivity of blood from healthy humans to the rAls3p-N vaccine protein. J Infect
Dis (2010) 201(3):473–7. doi:10.1086/649901
81. Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, et al. NDV-3, a
recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus,
is safe and immunogenic in healthy adults. Vaccine (2012) 30(52):7594–600.
doi:10.1016/j.vaccine.2012.10.038
82. Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, et al. The
immunogenicity and safety of different formulations of a novel Staphylo-
coccus aureus vaccine (V710): results of two phase I studies. Vaccine (2012)
30(9):1729–36. doi:10.1016/j.vaccine.2011.12.045
83. Ibarz-Pavón AB, Maclennan J, Andrews NJ, Gray SJ, Urwin R, Clarke SC, et al.
Changes in serogroup and genotype prevalence among carried meningococci
in the United Kingdom during vaccine implementation. J Infect Dis (2011)
204(7):1046–53. doi:10.1093/infdis/jir466
84. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al.
Serotype-specific changes in invasive pneumococcal disease after pneumococ-
cal conjugate vaccine introduction: a pooled analysis of multiple surveillance
sites. PLoS Med (2013) 10(9):e1001517. doi:10.1371/journal.pmed.1001517
85. Shirtliff ME, Peters BM, Jabra-Rizk MA. Cross-kingdom interactions: Candida
albicans and bacteria. FEMS Microbiol Lett (2009) 299(1):1–8. doi:10.1111/j.
1574-6968.2009.01668.x
86. Chotirmall SH, O’Donoghue E, Bennett K, Gunaratnam C, O’Neill SJ, McEl-
vaney NG. Sputum Candida albicans presages FEV(1) decline and hospital-
treated exacerbations in cystic fibrosis. Chest (2010) 138(5):1186–95. doi:10.
1378/chest.09-2996
87. Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, et al. Adapta-
tion of Pseudomonas aeruginosa in cystic fibrosis airways influences virulence
of Staphylococcus aureus in vitro and murine models of co-infection. PLoS One
(2014) 9(3):e89614. doi:10.1371/journal.pone.0089614
88. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of
a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
N Engl J Med (2002) 346(7):491–6. doi:10.1056/NEJMoa011297
89. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW,
et al. Effect of an investigational vaccine for preventing Staphylococcus aureus
infections after cardiothoracic surgery: a randomized trial. JAMA (2013)
309(13):1368–78. doi:10.1001/jama.2013.3010
90. Boles JW, Pitt ML, LeClaire RD, Gibbs PH, Torres E, Dyas B, et al. Generation
of protective immunity by inactivated recombinant staphylococcal enterotoxin
B vaccine in nonhuman primates and identification of correlates of immunity.
Clin Immunol (2003) 108(1):51–9. doi:10.1016/S1521-6616(03)00066-4
91. Stiles BG, Garza AR, Ulrich RG, Boles JW. Mucosal vaccination with
recombinantly attenuated staphylococcal enterotoxin B and protection in a
murine model. Infect Immun (2001) 69(4):2031–6. doi:10.1128/IAI.69.4.2031-
2036.2001
92. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, et al.
Development of a multicomponent Staphylococcus aureus vaccine designed to
counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012)
8(11):1585–94. doi:10.4161/hv.21872
93. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX,
a polysaccharide conjugate vaccine against S. aureus infection: from the lab
bench to phase III clinical trials. Vaccine (2004) 22(7):880–7. doi:10.1016/j.
vaccine.2003.11.034
94. O’Brien CN, Guidry AJ, Fattom A, Shepherd S, Douglass LW, Westhoff DC.
Production of antibodies to Staphylococcus aureus serotypes 5, 8, and 336 using
poly(DL-lactide-co-glycolide) microspheres. J Dairy Sci (2000) 83(8):1758–66.
doi:10.3168/jds.S0022-0302(00)75046-6
95. Zecconi A, Scali F. Staphylococcus aureus virulence factors in evasion from
innate immune defenses in human and animal diseases. Immunol Lett (2013)
150(1–2):12–22. doi:10.1016/j.imlet.2013.01.004
96. Kraus D, Peschel A. Staphylococcus aureus evasion of innate antimicrobial
defense. Future Microbiol (2008) 3(4):437–51. doi:10.2217/17460913.3.4.437
97. Rigby KM, DeLeo FR. Neutrophils in innate host defense against Staphylococ-
cus aureus infections. Semin Immunopathol (2012) 34(2):237–59. doi:10.1007/
s00281-011-0295-3
98. Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB. Nat-
ural antibodies in normal human serum inhibit Staphylococcus aureus cap-
sular polysaccharide vaccine efficacy. Clin Infect Dis (2012) 55(9):1188–97.
doi:10.1093/cid/cis624
99. Ehrhardt GR, Hijikata A, Kitamura H, Ohara O, Wang JY, Cooper MD. Dis-
criminating gene expression profiles of memory B cell subpopulations. J Exp
Med (2008) 205(8):1807–17. doi:10.1084/jem.20072682
100. Kobrynski LJ, Tanimune L, Kilpatrick L, Campbell DE, Douglas SD. Produc-
tion of T-helper cell subsets and cytokines by lymphocytes from patients
with chronic mucocutaneous candidiasis. Clin Diagn Lab Immunol (1996)
3(6):740–5.
101. Turner DL, Gordon CL, Farber DL. Tissue-resident T cells, in situ immu-
nity and transplantation. Immunol Rev (2014) 258(1):150–66. doi:10.1111/
imr.12149
102. Fowler VG Jr, Proctor RA. Where does a Staphylococcus aureus vaccine stand?
Clin Microbiol Infect (2014) 20(Suppl 5):66–75. doi:10.1111/1469-0691.12570
103. Schreiner J, Kretschmer D, Klenk J, Otto M, Bühring HJ, Stevanovic S, et al.
Staphylococcus aureus phenol-soluble modulin peptides modulate dendritic
cell functions and increase in vitro priming of regulatory T cells. J Immunol
(2013) 190(7):3417–26. doi:10.4049/jimmunol.1202563
104. Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, Allantaz F, et al.
Enhanced monocyte response and decreased central memory T cells in children
with invasive Staphylococcus aureus infections. PLoS One (2009) 4(5):e5446.
doi:10.1371/journal.pone.0005446
105. Rabe H, Nordström I, Andersson K, Lundell AC, Rudin A. Staphylococ-
cus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+)
CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis. Immunology (2014)
141(3):467–81. doi:10.1111/imm.12209
106. Chen Z, Han Y, Gu Y, Liu Y, Jiang Z, Zhang M, et al. CD11c(high)CD8+
regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-
Fas pathway. J Immunol (2013) 190(12):6145–54. doi:10.4049/jimmunol.
1300060
107. Farkas T, Thornton SA, Wilton N, Zhong W, Altaye M, Jiang X. Homologous
versus heterologous immune responses to Norwalk-like viruses among crew
members after acute gastroenteritis outbreaks on 2 US Navy vessels. J Infect Dis
(2003) 187(2):187–93. doi:10.1086/367809
108. Díaz I, Gimeno M, Darwich L, Navarro N, Kuzemtseva L, López S, et al. Char-
acterization of homologous and heterologous adaptive immune responses in
porcine reproductive and respiratory syndrome virus infection. Vet Res (2012)
43:30. doi:10.1186/1297-9716-43-30
109. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly
protective universal influenza vaccine. Nat Med (2010) 16(12):1389–91. doi:
10.1038/nm1210-1389
110. Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immu-
nity and the inflammatory response. Trends Immunol (2003) 24(9):474–8.
doi:10.1016/S1471-4906(03)00228-X
111. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, et al. Clin-
ical trial of safety and efficacy of INH-A21 for the prevention of nosocomial
staphylococcal bloodstream infection in premature infants. J Pediatr (2007)
151(3):260–5, 265.e1. doi:10.1016/j.jpeds.2007.04.060
112. Burnside K, Lembo A, Harrell MI, Klein JA, Lopez-Guisa J, Siegesmund AM,
et al.Vaccination with a UV-irradiated genetically attenuated mutant of Staphy-
lococcus aureus provides protection against subsequent systemic infection.
J Infect Dis (2012) 206(11):1734–44. doi:10.1093/infdis/jis579
113. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, et al. Assessment of an
anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphy-
lococcus aureus-induced pneumonia. Antimicrob Agents Chemother (2014)
58(2):1108–17. doi:10.1128/AAC.02190-13
114. Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibod-
ies mediate protection against Staphylococcus aureus pneumonia. Infect Immun
(2009) 77(7):2712–8. doi:10.1128/IAI.00115-09
115. Mocca CP, Brady RA, Burns DL. Role of antibodies in protection elicited by
active vaccination with genetically inactivated alpha hemolysin in a mouse
model of Staphylococcus aureus skin and soft tissue infections. Clin Vaccine
Immunol (2014) 21(5):622–7. doi:10.1128/CVI.00051-14
116. Yoong P, Pier GB. Antibody-mediated enhancement of community-acquired
methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A
(2010) 107(5):2241–6. doi:10.1073/pnas.0910344107
www.frontiersin.org September 2014 | Volume 5 | Article 463 | 19
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yeaman et al. Convergent immunity for S. aureus vaccines
117. Weems JJJr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, et al.
Phase II, randomized, double-blind, multicenter study comparing the safety
and pharmacokinetics of tefibazumab to placebo for treatment of Staphylo-
coccus aureus bacteremia. Antimicrob Agents Chemother (2006) 50(8):2751–5.
doi:10.1128/AAC.00096-06
118. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect
Dis (2012) 54(8):1179–86. doi:10.1093/cid/cis033
119. Seok J,Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic
responses in mouse models poorly mimic human inflammatory diseases. Proc
Natl Acad Sci U S A (2013) 110(9):3507–12. doi:10.1073/pnas.1222878110
120. Kim HK, Missiakas D, Schneewind O. Mouse models for infectious dis-
eases caused by Staphylococcus aureus. J Immunol Methods (2014) 410:88–99.
doi:10.1016/j.jim.2014.04.007
121. Sung JM, Lloyd DH, Lindsay JA. Staphylococcus aureus host specificity: com-
parative genomics of human versus animal isolates by multi-strain microarray.
Microbiology (2008) 154(Pt 7):1949–59. doi:10.1099/mic.0.2007/015289-0
122. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. Vaccine review: “Staphylococ-
cus aureus vaccines: problems and prospects”. Vaccine (2013) 31(25):2723–30.
doi:10.1016/j.vaccine.2013.04.002
123. Ahn SH, Tsalik EL, Cyr DD, Zhang Y, van Velkinburgh JC, Langley RJ, et al. Gene
expression-based classifiers identify Staphylococcus aureus infection in mice and
humans. PLoS One (2013) 8(1):e48979. doi:10.1371/journal.pone.0048979
124. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, et al.
Global gene expression of methicillin-resistant Staphylococcus aureus USA300
during human and mouse infection. J Infect Dis (2014) 209(10):1542–50.
doi:10.1093/infdis/jit668
125. Casadevall A, Pirofski LA. Exploiting the redundancy in the immune system:
vaccines can mediate protection by eliciting “unnatural” immunity. J Exp Med
(2003) 197(11):1401–4. doi:10.1084/jem.20030637
126. Jenner E. On Vaccination Against Smallpox: An Inquiry into the Causes and
Effects of the Variole Vaccine, or Cow Pox. London: Sampson Low (1798).
127. Murphy SG. Tetanus toxin and antigenic derivatives. II. Effect of protein
and formaldehyde concentration on toxoid formation. J Bacteriol (1967)
94(3):586–9.
128. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C,
et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny:
consensus sequence for an AIDS vaccine design? J Virol (2002) 76(11):5435–51.
doi:10.1128/JVI.76.11.5435-5451.2002
129. Koita OA, Dabitao D, Mahamadou I, Tall M, Dao S, Tounkara A, et al.
Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in
Bamako, Mali and Providence, Rhode Island. Hum Vaccin (2006) 2(3):119–28.
doi:10.4161/hv.2869
130. Giles BM, Ross TM. A computationally optimized broadly reactive antigen
(COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice
and ferrets. Vaccine (2011) 29(16):3043–54. doi:10.1016/j.vaccine.2011.01.100
131. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines
provide any cross-protection against serotype 19A? BMC Pediatr (2010) 10:4.
doi:10.1186/1471-2431-10-4
132. McNeely TB, Staub JM, Rusk CM, Blum MJ, Donnelly JJ. Antibody responses to
capsular polysaccharide backbone and O-acetate side groups of Streptococcus
pneumoniae type 9V in humans and rhesus macaques. Infect Immun (1998)
66(8):3705–10.
133. Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdottir I. Pneu-
mococcal serotype 19F conjugate vaccine induces cross-protective immunity
to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun
(2003) 71(5):2956–9. doi:10.1128/IAI.71.5.2956-2959.2003
134. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV.
Pneumococcal serotypes before and after introduction of conjugate vac-
cines, United States, 1999-2011(1.). Emerg Infect Dis (2013) 19(7):1074–83.
doi:10.3201/eid1907.121830
135. Hulten KG, Kaplan SL, Lamberth LB, Barson WJ, Romero JR, Lin PL, et al.
Changes in Streptococcus pneumoniae serotype 19A invasive infections in chil-
dren from 1993 to 2011. J Clin Microbiol (2013) 51(4):1294–7. doi:10.1128/
JCM.00058-13
136. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev
(1998) 11(3):430–9.
137. Fu Y, Ibrahim AS, Sheppard DC, Chen YC, French SW, Cutler JE, et al. Can-
dida albicans Als1p: an adhesin that is a downstream effector of the EFG1
filamentation pathway. Mol Microbiol (2002) 44:61–72. doi:10.1046/j.1365-
2958.2002.02873.x
138. Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, Welch WH, et al. Als3 is
a Candida albicans invasin that binds to cadherins and induces endocytosis by
host cells. PLoS Biol (2007) 5(3):e64. doi:10.1371/journal.pbio.0050064
139. Sheppard DC,Yeaman MR, Welch WH, Phan QT, Fu Y, Ibrahim AS, et al. Func-
tional and structural diversity in the Als protein family of Candida albicans.
J Biol Chem (2004) 279:30480–9. doi:10.1074/jbc.M401929200
140. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-
Th17 cells mediate protective adaptive immunity against Staphylococcus aureus
and Candida albicans infection in mice. PLoS Pathog (2009) 5(12):e1000703.
doi:10.1371/journal.ppat.1000703
141. Yeaman MR, Filler SG, Schmidt CS, Chaili S, Barr K, Wang H, et al. Efficacy
and immunologic mechanisms of NDV-3 vaccine in a murine model of MRSA
skin/skin structure infection. 52nd ICAAC. San Francisco, CA (2012). Abstract
No. G-868.
142. Festa M, Brun P, Piccinini R, Castagliuolo I, Basso B, Zecconi A. Staphylococcus
aureus Efb protein expression in Nicotiana tabacum and immune response to
oral administration. Res Vet Sci (2013) 94(3):484–9. doi:10.1016/j.rvsc.2012.
10.012
143. Camussone CM, Veaute CM, Pujato N, Morein B, Marcipar IS, Calvinho LF.
Immune response of heifers against a Staphylococcus aureus CP5 whole cell
and lysate vaccine formulated with ISCOM matrix adjuvant. Res Vet Sci (2014)
96(1):86–94. doi:10.1016/j.rvsc.2013.10.004
144. Camussone CM,Veaute CM, Porporatto C, Morein B, Marcipar IS, Calvinho LF.
Immune response of heifers against a Staphylococcus aureus CP5 whole cell vac-
cine formulated with ISCOMATRIX adjuvant. J Dairy Res (2013) 80(1):72–80.
doi:10.1017/S0022029912000593
145. Luo G, Hennessey JP Jr, Schmidt CS, Fu Y, Yeaman MR, Filler SG, et al. Human
vaccination with rAls3p-N produces antibodies that enhance phagocyte-
mediated killing of C. albicans and S. aureus and mitigate Als3p functions.
18th Congress of the International Society for Human and Animal Mycology.
Berlin (2012).
146. Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN. Polymicrobial blood-
stream infections involving Candida species: analysis of patients and review
of the literature. Diagn Microbiol Infect Dis (2007) 59(4):401–6. doi:10.1016/j.
diagmicrobio.2007.07.001
147. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, et al. Efficacy
of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and
mucosal candidiasis. J Infect Dis (2006) 194(2):256–60. doi:10.1086/504691
148. Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt CS, Hennessey JPJr, et al.
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell
immune response. Vaccine (2013) 31(47):5549–56. doi:10.1016/j.vaccine.2013.
09.016
149. Bär E, Gladiator A, Bastidas S, Roschitzki B, Acha-Orbea H, Oxenius A, et al.
A novel Th cell epitope of Candida albicans mediates protection from fungal
infection. J Immunol (2012) 188(11):5636–43. doi:10.4049/jimmunol.1200594
150. Pentier JM, Sewell AK, Miles JJ. Advances in T-cell epitope engineering. Front
Immunol (2013) 4:133. doi:10.3389/fimmu.2013.00133
151. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, et al.
Safety and immunogenicity of 26-valent group a Streptococcus vaccine in
healthy adult volunteers. Clin Infect Dis (2005) 41(8):1114–22. doi:10.1086/
444458
152. Zeng W, Horrocks KJ, Robevska G, Wong CY, Azzopardi K, Tauschek M,
et al. A modular approach to assembly of totally synthetic self-adjuvanting
lipopeptide-based vaccines allows conformational epitope building. J Biol
Chem (2011) 286(15):12944–51. doi:10.1074/jbc.M111.227744
153. Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery
systems. Pharm Res (2014). doi:10.1007/s11095-014-1419-y
154. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles.
Front Cell Infect Microbiol (2013) 3:13. doi:10.3389/fcimb.2013.00013
155. Lambrecht BN, Hammad H. Biology of lung dendritic cells at the origin of
asthma. Immunity (2009) 31(3):412–24. doi:10.1016/j.immuni.2009.08.008
156. Vander Lugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M, et al. Tran-
scriptional programming of dendritic cells for enhanced MHC class II antigen
presentation. Nat Immunol (2014) 15(2):161–7. doi:10.1038/ni.2795
157. Cruz LJ, Rueda F, Simón L, Cordobilla B, Albericio F, Domingo JC. Liposomes
containing NYESO1/tetanus toxoid and adjuvant peptides targeted to human
Frontiers in Immunology | Microbial Immunology September 2014 | Volume 5 | Article 463 | 20
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yeaman et al. Convergent immunity for S. aureus vaccines
dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine (Lond)
(2014) 9(4):435–49. doi:10.2217/NNM.13.66
158. Kaslow DC, Shiver JW. Clostridium difficile and methicillin-resistant Staphy-
lococcus aureus: emerging concepts in vaccine development. Annu Rev Med
(2011) 62:201–15. doi:10.1146/annurev-med-051109-101544
159. Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine (2012)
30(19):2921–7. doi:10.1016/j.vaccine.2011.11.006
Conflict of Interest Statement: The authors are founders, consultants, or employ-
ees of NovaDigm Therapeutics, Inc., which is developing novel vaccines targeting
Staphylococcus aureus and other pathogens. Some of the authors are inventors on
patent applications related to the use of Candida albicans Als3 as a vaccine anti-
gen targeting Candida spp. and the cross-kingdom protection targeting S. aureus.
NovaDigm has licensed the world-wide rights to this intellectual property.
Received: 09 July 2014; accepted: 10 September 2014; published online: 26 September
2014.
Citation: Yeaman MR, Filler SG, Schmidt CS, Ibrahim AS, Edwards JE Jr and Hen-
nessey JP Jr (2014) Applying convergent immunity to innovative vaccines targeting
Staphylococcus aureus. Front. Immunol. 5:463. doi: 10.3389/fimmu.2014.00463
This article was submitted to Microbial Immunology, a section of the journal Frontiers
in Immunology.
Copyright © 2014 Yeaman, Filler , Schmidt , Ibrahim, Edwards and Hennessey. This
is an open-access article distributed under the terms of the Creative Commons Attri-
bution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the origi-
nal publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
www.frontiersin.org September 2014 | Volume 5 | Article 463 | 21
